Johnson & Johnson Vision Care, Inc.

Clinical Study Protocol

Evaluation of Two Marketed Multifocal Contact Lenses

Protocol CR-5860

Version: 3.0, Amendment 2.0

Date: 01-SEP-2017

Investigational Products: Dailies Total 1* Multifocal Contact Lens and Biotrue ONEday® for Presbyopia Contact Lens.

Key Words: Presbyopia, Daily Disposable, Dispensing, Multifocal, Nesofilcon A, Delefilcon A.

Statement of Compliance to protocol, GCP and applicable regulatory guidelines:
This trial will be conducted in compliance with the protocol, the International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP), ISO 14155, the Declaration of Helsinki, and all applicable regulatory requirements.

Confidentiality Statement:
This document contains confidential information, which should not be copied, referred to, released or published without written approval from Johnson & Johnson Vision Care, Inc. The information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by International, Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision Care, Inc. Any supplemental information that may be added to this document is also confidential and proprietary to Johnson & Johnson Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this document.
# TABLE OF CONTENTS

- PROTOCOL TITLE, NUMBER, VERSION ................................................. 6
- SPONSOR NAME AND ADDRESS .................................................. 6
- MEDICAL MONITOR ........................................................................... 6
- AUTHORIZED SIGNATURES ............................................................... 7
- CHANGE HISTORY ........................................................................... 8
- SYNOPSIS .......................................................................................... 9
- Figure 1: Flowchart .......................................................................... 13
- COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS .... 14

## 1. INTRODUCTION AND BACKGROUND ........................................ 16

1.1. Name and Descriptions of Investigational Products ...................... 16
1.2. Intended Use of Investigational Products .................................. 16
1.3. Summary of Findings from Nonclinical Studies ......................... 16
1.4. Summary of Known Risks and Benefits to Human Subjects ........ 16
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study .......................................................... 16

## 2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES .......... 17

2.1. Objectives .................................................................................... 17
2.2. Endpoints .................................................................................... 17
2.3. Hypotheses .................................................................................. 17

## 3. TARGETED STUDY POPULATION ............................................ 18

3.1. General Characteristics ............................................................... 18
3.2. Inclusion Criteria ......................................................................... 18
3.3. Exclusion Criteria .......................................................................... 18
3.4. Enrollment Strategy ...................................................................... 19

## 4. STUDY DESIGN AND RATIONALE ............................................ 19

4.1. Description of Study Design ....................................................... 19
4.2. Study Design Rationale ............................................................... 19
4.3. Enrollment Target and Study Duration ...................................... 19

## 5. TEST ARTICLE ALLOCATION AND MASKING .................... 19

5.1. Test Article Allocation ................................................................. 19
5.2. Masking ....................................................................................... 20
5.3. Procedures for Maintaining and Breaking Randomization Codes .... 20

## 6. STUDY INTERVENTION ............................................................. 21
6.1. Identity of Test Articles.................................................................21
Table 1: Test Articles.........................................................................21
6.2. Ancillary Supplies/Products.........................................................22
Table 2: Ancillary Supplies .................................................................22
6.3. Administration of Test Articles..................................................22
6.4. Packaging and Labeling...............................................................22
6.5. Storage Conditions.....................................................................22
6.6. Collection and Storage of Samples.............................................22
6.7. Accountability of Test Articles....................................................22
7. STUDY EVALUATIONS....................................................................24
7.1. Time and Event Schedule.............................................................24
Table 3: Time and Events ..................................................................24
7.2. Detailed Study Procedures..........................................................28
  VISIT 1.........................................................................................28
  VISIT 2.........................................................................................33
  VISIT 3.........................................................................................37
  VISIT 4.........................................................................................40
  VISIT 5.........................................................................................44
  VISIT 6.........................................................................................47
  FINAL EVALUATION.................................................................50
7.3. Unscheduled Visits.....................................................................50
7.4. Laboratory Procedures.................................................................51
8. SUBJECTS COMPLETION/WITHDRAWAL......................................52
  8.1. Completion Criteria.................................................................52
  8.2. Withdrawal/Discontinuation from the Study............................52
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION...53
10. DEVIATIONS FROM THE PROTOCOL.........................................53
11. STUDY TERMINATION.................................................................53
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS..54
13. ADVERSE EVENTS.....................................................................55
  13.1. Definitions and Classifications..............................................55
  13.2. Assessing Adverse Events....................................................57
    13.2.1 Causality Assessment......................................................57
    13.2.2 Severity Assessment......................................................58
13.3. Documentation and Follow-Up of Adverse Events ......................... 58
13.4. Reporting Adverse Events ........................................... 59
   13.4.1 Reporting Adverse Events to Sponsor .............................. 60
   13.4.2 Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities ........................................... 60
13.5. Event of Special Interest ............................................. 61
13.6. Reporting of Pregnancy ................................................ 61
14. STATISTICAL METHODS .................................................. 61
   14.1. General Considerations ............................................. 61
   14.2. Sample Size Justification .......................................... 61
   14.3. Analysis Populations ................................................ 62
   14.4. Level of Statistical Significance ................................... 62
   14.5. Primary Analysis ................................................... 62
   14.6. Secondary Analysis .................................................. 63
   14.7. Other Exploratory Analyses ........................................ 63
   14.8. Interim Analysis ..................................................... 63
   14.9. Procedure for Handling Missing Data and Drop-Outs ............. 63
   14.10. Procedure for Reporting Deviations from Statistical Plan ...... 63
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING ......................... 64
   15.1. Electronic Case Report Form/Data Collection ....................... 64
   15.2. Subject Record ..................................................... 64
16. DATA MANAGEMENT ...................................................... 65
   16.1. Access to Source Data/Document ................................... 65
   16.2. Confidentiality of Information .................................... 65
   16.3. Data Quality Assurance ............................................ 65
17. MONITORING .............................................................. 66
18. ETHICAL AND REGULATORY ASPECTS ................................... 66
   18.1. Study-Specific Design Considerations ............................. 66
   18.2. Investigator Responsibility ........................................ 66
   18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB) ........................... 67
   18.4. Informed Consent .................................................. 68
   18.5. Privacy of Personal Data .......................................... 68
19. STUDY RECORD RETENTION ............................................. 69
20. FINANCIAL CONSIDERATIONS ........................................... 70
PROTOCOL TITLE, NUMBER, VERSION
Title: Evaluation of Two Marketed Multifocal Contact Lenses
Protocol Number: CR-5860
Version: 3.0, Amendment 2.0
Date: 01-SEP-2017

SPONSOR NAME AND ADDRESS
Johnson & Johnson Vision Care, Inc. (JJVC)
7500 Centurion Parkway,
Jacksonville, FL 32256

MEDICAL MONITOR
NAME: Thomas R. Karkkainen, OD, MS, FAAO
TITLE: Sr. Principal Research Optometrist
ADDRESS: 7500 Centurion Parkway, Jacksonville, Florida 32256
E-MAIL: TKarkkai@its.jnj.com

The Medical Monitor must be notified by the clinical institution/site by e-mail, fax, or telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contacted during business hours for adverse event questions. General study related questions should be directed towards your assigned clinical research associate.

The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.
AUTHORIZED SIGNATURES

The signature below constitutes the approval of this protocol and the attachments, and provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal regulations, ICH guidelines, ISO 14155 and the Declaration of Helsinki.

Author

Thomas R. Karkkainen, OD, MS, FAAO
Title: Sr. Principal Research Optometrist

Clinical Operations Manager

Clinical Operations Manager

Biostatistician

Biostatistician IV

Data Management

Clinical Project Manager-Data and Systems

Approver

Presbyopia Platform Sr. Manager
## CHANGE HISTORY

<table>
<thead>
<tr>
<th>Version</th>
<th>Originator</th>
<th>Description of Change(s) and Section Number(s) Affected</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Tom Karkkainen</td>
<td>Original Protocol</td>
<td>23-June-2017</td>
</tr>
<tr>
<td>2.0</td>
<td></td>
<td>Change Secondary Objective on page 17 to CLUE vision score.</td>
<td>30-June-2017</td>
</tr>
<tr>
<td>3.0</td>
<td>Tom Karkkainen</td>
<td>In section 2.3 updated hypotheses.</td>
<td>01-September-2017</td>
</tr>
</tbody>
</table>
## SYNOPSIS

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>Evaluation of Two Marketed Multifocal Contact Lenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>JJVC, 7500 Centurion Parkway, Jacksonville, FL 32256</td>
</tr>
<tr>
<td>Clinical Phase</td>
<td>Development phase, phase 0 (Research)</td>
</tr>
<tr>
<td>Trial Registration</td>
<td>This study will be registered on ClinicalTrials.gov by the Sponsor</td>
</tr>
<tr>
<td>Test Article(s)</td>
<td>Investigational Products: Biotrue ONEday and Oneday for Presbyopia and Dailies Total 1 Multifocal Contact Lenses.</td>
</tr>
<tr>
<td>Control Products:</td>
<td>None</td>
</tr>
<tr>
<td>Wear and Replacement</td>
<td>Wear Schedule: Daily</td>
</tr>
<tr>
<td>Schedules</td>
<td>Replacement Schedule: Daily Disposable</td>
</tr>
<tr>
<td>Objectives</td>
<td>Primary Objective:</td>
</tr>
<tr>
<td></td>
<td>To evaluate the visual performance of a marketed multifocal contact lens in a population of presbyopes with myopia and hyperopia.</td>
</tr>
<tr>
<td></td>
<td>Secondary Objective:</td>
</tr>
<tr>
<td></td>
<td>CLUE vision score</td>
</tr>
<tr>
<td>Study Endpoints</td>
<td>Primary endpoints:</td>
</tr>
<tr>
<td></td>
<td>The primary endpoints in this study are distance and near binocular high luminance, high contrast visual performance on logMAR scale.</td>
</tr>
<tr>
<td></td>
<td>Secondary endpoint:</td>
</tr>
<tr>
<td></td>
<td>The secondary endpoint is overall quality of vision assessed using the Contact Lens User Evaluation questionnaire (CLUE™).</td>
</tr>
<tr>
<td></td>
<td>Other endpoint:</td>
</tr>
<tr>
<td></td>
<td>Ease of fit as evaluated by the number of lenses used to optimize.</td>
</tr>
</tbody>
</table>
| Study Design | This is a single-masked, randomized, cross-over, dispensing pilot study. There will be six study visits. Visit 1 will include baseline measurements and screening to ensure eligibility. Eligible subjects will be randomized and fit in one of the study lenses and dispensed for 2-4 days. At Visit 2 additional measurements will be performed and it will be determined if lens optimization is required and lenses dispensed for an additional 6-8 days. At Visit 3 the primary endpoint data used for analysis will be collected. There will be a 4-8-day washout before the subject will be fit with the 2nd lens at Visit 4 and dispensed for 2-4 days. At Visit 5 additional measurements will be performed and it will be determined if lens optimization is required and lenses dispensed for an additional 6-8 days. At Visit 6 the primary endpoint data used for analysis will be collected.

See the flow chart at the end of the synopsis table for the schematic of the study visits and procedures of main observations. |
| Sample Size | A total of approximately 80 eligible subjects will be enrolled into the study with 60 (30 myopes and 30 hyperopes) subjects targeted to complete the study. An attempt will be made to evenly distribute the subjects across the following ADD groups. |
| Study Duration | The study recruitment is anticipated to be approximately 3 weeks and the data collection approximately and additional 3 weeks. |
| Anticipated Study Population | Habitual contact lens wearer who are myopic or hyperopic and have presbyopia. |
| Eligibility Criteria | Potential subjects must satisfy all of the following criteria to be enrolled in the study:
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. The subject must be between at least 40 years of age and not greater than 70 years of age.
4. The subject’s distance spherical equivalent refraction must be in the range of +3.75 D to -3.75 D. |

<table>
<thead>
<tr>
<th>ADD 0.75 D to 1.50 D</th>
<th>ADD 1.75 D to 2.50 D</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Subjects</td>
<td>30 Subjects</td>
</tr>
</tbody>
</table>
5. The subject’s refractive cylinder must be $\leq -0.75$ D in each eye.
6. The subject’s ADD power must be in the range of $+0.75$ D to $+2.50$ D in each eye.
7. The subject must have best corrected visual acuity of $20/20^3$ or better in each eye.
8. The subject must own a pair of wearable spectacles if required for their distance vision.
9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month or more duration).
10. The subject must either be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".

Potential subjects who meet any of the following criteria will be excluded from participating in the study:
1. Ocular or systemic allergies or disease, or use of medication which might interfere with contact lens wear.
2. Pregnancy or lactation.
3. Currently diagnosed with diabetes.
4. Infectious diseases (e.g. hepatitis, tuberculosis) or an immune-suppressive disease (e.g. HIV).
5. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
6. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions.
7. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
8. A history of amblyopia, strabismus or binocular vision abnormality.
9. Any ocular infection or inflammation.
10. Any ocular abnormality that may interfere with contact lens wear.
11. Use of any ocular medication, with the exception of rewetting drops.
12. History of herpetic keratitis.
13. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
<table>
<thead>
<tr>
<th><strong>14. Employee of clinical site (e.g., Investigator, Coordinator, Technician)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disallowed Medications/Interventions</strong></td>
</tr>
<tr>
<td><strong>Measurements and Procedures</strong></td>
</tr>
<tr>
<td><strong>Microbiology or Other Laboratory Testing</strong></td>
</tr>
<tr>
<td><strong>Study Termination</strong></td>
</tr>
<tr>
<td><strong>Ancillary Supplies/ Study-Specific Materials</strong></td>
</tr>
<tr>
<td><strong>Principal Investigator(s) and Study Institution(s)/Site(s)</strong></td>
</tr>
</tbody>
</table>
Figure 1: Flowchart

60 Subjects (30 Myopes and 30 Hyperopes) to Complete

Potential Subjects Identified Based On:
- Age: 40-70 yrs (inclusive)
- Habitual contact lens wearers with Presbyopic correction or symptoms
- Refraction: Spherical Equivalent +3.75D to -3.75D
- Cylinder: 0.0/3.0
- Add: +0.75D to +2.50D
- Visual Acuity: Best corrected 20/30-3 or better in each eye

Informed Consent
Eligibility Criteria
Baseline Information
- Habitual lens type, modality, and contact lens history. Wear Time
- Baseline and CLDEQ-8 Questionnaire
- Pupillometry, Keratometry
- Subjective refraction, Add Determination, Ocular Dominance, Add Refinement
- Biomicroscopy

Trial Fitting #1
- Randomization ID, Lens Selection
- Lens Insertion and Lens Damage
- Lens Setting, Visual Satisfaction, Visual Acuity, Over-Reflection
- Lens Fit Assessment

Modifications (if necessary)

Yes

No

After 10 Minute Settling
- Post-fit PRO Questionnaire
- Exit Visual Acuity
- Dispensing Criteria, Subject Instructions
- Schedule Follow-up 3rd Day

Visit 2 Follow-up
- Medical History and Concomitant Medication Review
- Wear Time and Compliance
- PRO and CLDEQ-8 Questionnaire
- Ocular Symptoms, Visual Satisfaction
- Entrance Visual Acuity, Over Refraction
- Determination of Lens Optimality

Modifications (if necessary)

Yes

No

After 10 Minute Settling
- Lens Fit Assessment
- Collection of Unworn Lens (if applicable)
- PRO Questionnaire
- Exit Visual Acuity
- Dispensing Criteria, Subject Instructions
- Schedule Follow-up 3rd Day

Visit 3 Follow-up
- Medical History and Concomitant Medication Review
- Wear Time and Compliance
- PRO and CLDEQ-8 Questionnaire
- Ocular Symptoms, Visual Satisfaction
- Entrance Visual Acuity, Binocular Over-Reflection, Lens Fit Assessment
- logMAR Visual Performance, Biomicroscopy
- Exit Visual Acuity
- Wash-out Period 6-2 Days

Visit 4 Baseline
- Medical History and Concomitant Medication Review
- Baseline and CLDEQ-8 Questionnaire
- Entrance Visual Acuity
- Biomicroscopy
- Compliance

Final Evaluation
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADD</td>
<td>Plus Power Required for Near Use</td>
</tr>
<tr>
<td>ADE</td>
<td>Adverse Device Effect</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event/Adverse Experience</td>
</tr>
<tr>
<td>BCVA</td>
<td>Best Corrected Visual Acuity</td>
</tr>
<tr>
<td>BSCVA</td>
<td>Best Spectacle Corrected Visual Acuity</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CLUE</td>
<td>Contact Lens User Experience</td>
</tr>
<tr>
<td>CLDEQ-8</td>
<td>8-Item Contact Lens Dry Eye Questionnaire</td>
</tr>
<tr>
<td>COAS</td>
<td>Complete Ophthalmic Analysis System</td>
</tr>
<tr>
<td>COM</td>
<td>Clinical Operations Manager</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical Research Associate</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>CT</td>
<td>Center Thickness</td>
</tr>
<tr>
<td>CTP</td>
<td>Clinical Technical Procedure</td>
</tr>
<tr>
<td>D</td>
<td>Diopter</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic Case Report Form</td>
</tr>
<tr>
<td>EDC</td>
<td>Electronic Data Capture</td>
</tr>
<tr>
<td>ETDRS</td>
<td>Early Treatment Diabetic Retinopathy Study</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator's Brochure</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonization</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exemption</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IRT</td>
<td>Item Response Theory</td>
</tr>
<tr>
<td>ISO</td>
<td>International Organization for Standardization</td>
</tr>
<tr>
<td>ITT</td>
<td>Intent-to-Treat</td>
</tr>
<tr>
<td>JJVC</td>
<td>Johnson &amp; Johnson Vision Care, Inc.</td>
</tr>
<tr>
<td>LC</td>
<td>Limbus Center</td>
</tr>
<tr>
<td>LogMAR</td>
<td>Logarithm of Minimal Angle of Resolution</td>
</tr>
<tr>
<td>MedDRA®</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MOP</td>
<td>Manual of Procedures</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>OD</td>
<td>Right Eye</td>
</tr>
<tr>
<td>OHRP</td>
<td>Office for Human Research Protections</td>
</tr>
<tr>
<td>OHSR</td>
<td>Office for Human Subjects Research</td>
</tr>
<tr>
<td>OS</td>
<td>Left Eye</td>
</tr>
<tr>
<td>OU</td>
<td>Both Eyes</td>
</tr>
<tr>
<td>PD</td>
<td>Protocol Deviation</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PHI</td>
<td>Protected Health Information</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PIG</td>
<td>Patient Instruction Guide</td>
</tr>
<tr>
<td>PQC</td>
<td>Product Quality Complaint</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient Reported Outcome</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>QC</td>
<td>Quality Control</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event/Serious Adverse Experience</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SAS</td>
<td>Statistical Analysis System</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>UADE</td>
<td>Unanticipated Adverse Device Effect</td>
</tr>
<tr>
<td>USADE</td>
<td>Unanticipated Serious Adverse Device Effect</td>
</tr>
<tr>
<td>VA</td>
<td>Visual Acuity</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND BACKGROUND

Johnson & Johnson Vision recently launched a daily disposable multifocal contact lens, 1-Day ACUVUE® Brand MOIST® Multifocal. Since the launch of this lens additional daily disposable multifocal contact lenses have been approved and marketed. The purpose of this clinical study is to evaluate the performance of two of the newer competitor lenses that have been launched. The data will help to better understand the performance strengths and weaknesses of each product.

1.1. Name and Descriptions of Investigational Products

This study will test two (2) marketed multifocal contact lenses, Biotrue ONEday® for Presbyopia and Dailies Total 1® Multifocal Contact Lens. Further details about the test articles are found in Section 6 of this protocol.

1.2. Intended Use of Investigational Products

The intended use of the lenses is to correct distance spherical refractive error and presbyopia. Greater details on each of the marketed products can be found in the package insert in the appendices of this protocol.

1.3. Summary of Findings from Nonclinical Studies

Not Applicable – Marketed product only.

1.4. Summary of Known Risks and Benefits to Human Subjects

The contact lenses are currently marketed products that, like all multifocal contact lenses, act as a refractive media to correct for distance spherical refractive error and presbyopia. Beyond having their vision corrected by the contact lenses the subject will have no direct benefit from participating in the study.

The intent of these products is for use as a daily disposable contact lens that the subject wears while awake. The lenses are not intended for extended wear or reuse. This evaluation is for daily disposable modality only. Anticipated risks and adverse reactions with this lens are like other soft daily wear contact lenses used to correct presbyopia. A listing of examples of adverse reactions is found in the Section 13 of this protocol. The Investigator should follow normal clinical guidelines regarding examination and care of subjects who participate in this trial. For the most comprehensive clinical information regarding the marketed products refer to the package insert for the marketed product locate in the appendices of this clinical protocol.

1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study

A PubMed literature search using the term “Biotrue One day for Presbyopia” and “Dailies Total 1 Multifocal Contact Lens” revealed no results. Additional information regarding the marketed products can be found in the package inserts located in the appendices of this clinical protocol.
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES

2.1. Objectives

Primary Objective:
To evaluate the visual performance of a marketed multifocal contact lens in a population of presbyopes with myopia and hyperopia.

Secondary Objective:
CLUE vision score

Exploratory Objective: Not Applicable

2.2. Endpoints

Primary Endpoint
The primary endpoint in this study are distance and near binocular high luminance, high contrast visual performance on logMAR scale.

Secondary Endpoint
The secondary endpoint is overall quality of vision assessed using the Contact Lens User Evaluation questionnaire (CLUE™). CLUE is a validated Patient Reported Outcome (PRO) questionnaire developed to measure general and throughout the day comfort/vision, as well as symptoms of discomfort/poor vision, lens handling and packaging. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. A 5-point increase in an average CLUE score translates into 10% shift in the distribution of scores for population of soft contact lens wearers. Both primary and secondary endpoints will be assessed after wearing each optimized study lens for 6-8 days.

Other Observations:
The other endpoints are the ease of fit as measured by the total number of lenses required to optimize vision each lens type and the ocular physiological response are measured by the average corneal staining grade using the FDA biomicroscopy scale for corneal staining. The data for the ease of fit and corneal staining will be summarized.

2.3. Hypotheses

Primary Hypotheses
1. After 8-12 days of lens wear, the distance, binocular, high luminance, high contrast visual performance of the two test lenses will be superior to +0.01 logMAR.
2. After 8-12 days of lens wear, the near, binocular, high luminance, high contrast visual performance of the two test lenses will be superior to +0.17 logMAR.

Secondary Hypothesis
1. After 8-12 days of lens wear, the overall quality of vision of the two test lenses will be superior to 32 CLUE points.

Other Hypotheses: Not applicable.
3. TARGETED STUDY POPULATION

3.1. General Characteristics

Healthy male and female volunteers who are presbyopic will be recruited for the study. The subjects will all be adapted wearers of soft contact lenses in both eyes.

3.2. Inclusion Criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. The subject must be between at least 40 years of age and not greater than 70 years of age.
4. The subject’s distance spherical equivalent refraction must be in the range of +3.75 D to -3.75 D.
5. The subject’s refractive cylinder must be ≤ -0.75 D in each eye.
6. The subject’s ADD power must be in the range of +0.75 D to +2.50 D in each eye.
7. The subject must have best corrected visual acuity of 20/20³ or better in each eye.
8. The subject must own a pair of wearable spectacles if required for their distance vision.
9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month or more duration).
10. The subject must either be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or respond positively to at least one symptom on the “Presbyopic Symptoms Questionnaire”.

3.3. Exclusion Criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Ocular or systemic allergies or disease, or use of medication which might interfere with contact lens wear.
2. Pregnancy or lactation.
3. Currently diagnosed with diabetes.
4. Infectious diseases (e.g. hepatitis, tuberculosis) or an immune-suppressive disease (e.g. HIV).
5. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
6. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions.
7. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
8. A history of amblyopia, strabismus or binocular vision abnormality.
9. Any ocular infection or inflammation.
10. Any ocular abnormality that may interfere with contact lens wear.
11. Use of any ocular medication, with the exception of rewetting drops.
12. History of herpetic keratitis.
13. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
14. Employee of clinical site (e.g., Investigator, Coordinator, Technician)

3.4. Enrollment Strategy
Study subjects will be recruited from the clinical site’s subject database.

4. STUDY DESIGN AND RATIONALE

4.1. Description of Study Design
This is a single-masked, crossover, randomized, dispensing clinical trial. A total of approximately 60 eligible subjects will be targeted to complete the study. The subjects will be randomized and fit in the study lens and wear each lens type for approximately three days then undergo optimization, if required, and wear the optimized pair for approximately 1 week. The primary endpoint is visual performance. The secondary endpoint is the CLUE vision score.

4.2. Study Design Rationale
The study is a prospective, bilateral, crossover evaluation. As we have no historical clinical data on the lenses being tested the study design includes a washout period to minimize any potential carry-over effect.

4.3. Enrollment Target and Study Duration
Approximately 80 subjects will be recruited (40 myopes and 40 hyperopes) with an aim of completing a total of 60 subjects in the final cohort.

5. TEST ARTICLE ALLOCATION AND MASKING

5.1. Test Article Allocation
The study lenses will be worn in a bilateral and random fashion using a 2×2 crossover design with 2 lens types and 2 periods. Using a computer-generated randomization scheme provided by the study biostatistician, each subject will randomly be assigned to one of two unique sequences of the two lens types (Test1/Test2 or Test2/Test1). Randomization will be stratified by site.

Permuted block randomization will be used to avoid bias in the assignment of subjects to treatment, and to enhance the validity of statistical comparisons across treatment groups. Each block will contain two different lens trial sequences.
The order of lens wear will be based on the randomization scheme assigned to the study site. The study site will follow the randomization scheme provided and will complete enrollment according to the randomization list and will not pre-select or assign subjects.

This is a single masked study: subjects will be masked to the identities of the study lenses.

5.2. Masking

Masking will be used to reduce potential bias. Subjects will be unaware of the identity of the investigational product. Investigators and clinical site personnel involved in the data collection will not be masked as to the identity of the investigational product.

Under normal circumstances, the mask should not be broken until all subjects have completed the study and the database is finalized. Otherwise, the mask should be broken only if specific emergency treatment/course of action would be dictated by knowing the treatment status of the subject. In such cases, the Investigator may, in an emergency, contact the medical monitor. In the event the mask is broken; the Sponsor must be informed as soon as possible. The date, time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatment assignment to the clinical site or Sponsor personnel.

Subjects who have had their treatment assignment unmasked are expected to return for all remaining scheduled evaluations. Subjects who are discontinued may be replaced.

5.3. Procedures for Maintaining and Breaking Randomization Codes

The test articles mask shall not be broken unless information concerning the lens type is necessary for the urgent medical treatment of a subject. The Sponsor must be notified before the mask is broken.

When dispensing test articles, the following steps should be followed to maintain randomization codes:

1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule/randomization scheme to obtain the test article assignment for that subject prior to dispensing
2. Investigator or designee will record the subject’s number on the appropriate line of the randomization scheme.
3. Investigator or designee will pull the appropriate test articles from the study supply. All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the “Dispensed” section
6. STUDY INTERVENTION

6.1. Identity of Test Articles

The following contact lenses will be used in this study:

Table 1: Test Articles

<table>
<thead>
<tr>
<th></th>
<th>Test 1</th>
<th>Test 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Dailies Total 1® Multifocal Contact Lens</td>
<td>Biotrue ONEday® Contact Lens</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Alcon®</td>
<td>Bausch and Lomb</td>
</tr>
<tr>
<td>Compass Protocol(s)</td>
<td>Over-labeled</td>
<td>Over-labeled</td>
</tr>
<tr>
<td>Number or Other Identifier</td>
<td>Over-labeled</td>
<td>Over-labeled</td>
</tr>
<tr>
<td>Lens Material</td>
<td>delefilcon A</td>
<td>nesofilcon A</td>
</tr>
<tr>
<td>Nominal Base Curve @ 22°C</td>
<td>8.5</td>
<td>8.6</td>
</tr>
<tr>
<td>Nominal Diameter @ 22°C</td>
<td>14.1</td>
<td>14.2</td>
</tr>
<tr>
<td>Nominal Distance Powers (D)</td>
<td>+4.25 D to -4.00 D in 0.25D steps</td>
<td>+4.50 D to -4.00 D in 0.25 D steps</td>
</tr>
<tr>
<td>Nominal ADD Powers (D)</td>
<td>LO MED HI</td>
<td>Low (+0.75 to +1.50 Spectacle Add)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High (+1.75 to +2.50 Spectacle Add)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Water Content</td>
<td>33% (Core Water Content)</td>
<td>78%</td>
</tr>
<tr>
<td>Center Thickness</td>
<td>0.09 mm (-1.00 D)</td>
<td>0.1 mm (-3.00 D)</td>
</tr>
<tr>
<td>Oxygen Permeability (Dk)</td>
<td>156 @ -3.00D</td>
<td>42 @center for -3.00 D</td>
</tr>
<tr>
<td>Modality in Current Study</td>
<td>Daily Disposable</td>
<td>Daily Disposable</td>
</tr>
<tr>
<td>Replacement Frequency</td>
<td>Daily</td>
<td>Daily</td>
</tr>
<tr>
<td>Packaging Form (vial, blister, etc.)</td>
<td>Blister</td>
<td>Blister</td>
</tr>
</tbody>
</table>

Each subject what completes the study will wear approximately 22 lenses. As there are 60 subjects approximately 1320 lenses would be used for each lens type.
6.2. Ancillary Supplies/Products

The following solutions will be used in this study:

Table 2: Ancillary Supplies

<table>
<thead>
<tr>
<th>Solution Name/Description</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eye-Cept® Rewetting drops</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Optics Laboratory</td>
</tr>
<tr>
<td>Preservative</td>
<td>Non-preserved</td>
</tr>
</tbody>
</table>

6.3. Administration of Test Articles

Test articles will be dispensed to subject meeting all eligibility requirements, including any dispensing requirements set forth in this clinical protocol. Subjects will be dispensed an adequate supply of test articles to complete the study. Lost or damaged test articles may be replaced at the discretion of the Investigator and/or the Sponsor.

6.4. Packaging and Labeling

The test articles will be packaged in blisters, as the primary packaging. The test article will be over-labeled to mask the subject to the identity of the lens. The test articles will be in investigational cartons sealed with a tamper evident seal, commercial cartons, or in plastic bags as the secondary packaging form. The sample study label is shown below:

6.5. Storage Conditions

Test articles will be maintained at ambient temperatures at the clinical site. Test articles must be kept under secure conditions.

6.6. Collection and Storage of Samples

When possible, any lens or test article associated with an Adverse Events and/or a Product Quality Complaint must be retained and stored in a glass vial with moderate solution pending directions from the sponsor for potential return to JJVC.

6.7. Accountability of Test Articles

JJVC will provide the Investigator with sufficient quantities of study articles and supplies to complete the investigation. The Investigator is asked to retain all lens shipment documentation for the test article accountability records.
Test article must be kept in a locked storage cabinet, accessible only to those assigned by the Investigator for dispensing. The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:

1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued for the subject to replace appropriately between visits
2. What was returned to the Investigator unused
3. The number and reason for unplanned replacements.

The Investigator will collect all unused test articles from the subjects at the end of the subject’s participation. Subject returned unused test articles must be separated from the clinical study inventory of un-dispensed test articles, and must be labeled with the subject number and date of return. Following final reconciliation of test articles by the monitor, the Investigator or monitor will package and return all unused test articles to JJVC.

If there is a discrepancy between the shipment documents and the contents, contact the study monitor immediately.
## 7. STUDY EVALUATIONS

### 7.1. Time and Event Schedule

Table 3: Time and Events

<table>
<thead>
<tr>
<th>Visit Information</th>
<th>Visit 1</th>
<th>Visit 2</th>
<th>Visit 3</th>
<th>Visit 4</th>
<th>Visit 5</th>
<th>Visit 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening, Baseline, Treatment 1</td>
<td>Day 1</td>
<td>Day 3±1 from V1</td>
<td>Day 7±1 from V2</td>
<td>Day 6±2 from V3</td>
<td>Day 3±1 from V4</td>
<td>Day 7±1 from V5</td>
</tr>
<tr>
<td>Treatment 1 Follow-up 1</td>
<td>2.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
</tr>
<tr>
<td>Treatment 1 Follow-up 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Estimated Visit Duration**
- **Statement of Informed Consent**
- **x**
- **Demographics**
- **x**
- **Medical History/Concomitant Medications**
- **x**
- **Adverse Event Medical History/Concomitant Medications Review**
- **x**
- **Habitual Contact Lens Information**
- **x**
- **Contact Lens History**
- **x**
- **Wear Time**
- **x**
- **Screening Inclusion/Exclusion**
- **x**
<table>
<thead>
<tr>
<th>Visit Information</th>
<th>Visit 1 (Screening, Baseline, Treatment 1)</th>
<th>Visit 2 (Treatment 1 Follow-up 1)</th>
<th>Visit 3 (Treatment 1 Follow-up 2)</th>
<th>Visit 4 (Baseline 2 Treatment 2)</th>
<th>Visit 5 (Treatment 2 Follow-up 1)</th>
<th>Visit 6 (Treatment 2 Follow-up 2 Final Evaluation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time Point</td>
<td>Day 1</td>
<td>Day 3±1 from V1</td>
<td>Day 7±1 from V2</td>
<td>Day 6±2 from V3</td>
<td>Day 3±1 from V4</td>
<td>Day 7±1 from V5</td>
</tr>
<tr>
<td>Estimated Visit Duration</td>
<td>2.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
</tr>
<tr>
<td>Criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline PRO Questionnaire</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLDEQ-8 Questionnaire</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>PRO Questionnaire</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Compliance</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Subject Reported Ocular Symptoms</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Screening Eligibility</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entrance Snellen Distance Visual Acuity</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Subjective Sphero-Cylindrical Refraction</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lens Removal</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Pupilometry</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keratometry</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Near Add Determination</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular Dominance</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Add Refinement</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Information</td>
<td>Estimated Visit Duration</td>
<td>Time Point</td>
<td>Near Visual Acuity</td>
<td>Biomicroscopy</td>
<td>Baseline Inclusion/Exclusion</td>
<td>Eligibility</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Visit 1</td>
<td>2.5 hours</td>
<td>Day 1</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit 2</td>
<td>1.5 hours</td>
<td>Day 3:1 from V1</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit 3</td>
<td>1.5 hours</td>
<td>Day 7:1 from V2</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit 4</td>
<td>1.5 hours</td>
<td>V3</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit 5</td>
<td>1.5 hours</td>
<td>Day 6:1 from V4</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit 6</td>
<td>1.5 hours</td>
<td>Final Evaluation</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Visit Information</td>
<td>Visit 1</td>
<td>Visit 2</td>
<td>Visit 3</td>
<td>Visit 4</td>
<td>Visit 5</td>
<td>Visit 6</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td>Screening, Baseline, Treatment 1</td>
<td>Treatment 1 Follow-up 1</td>
<td>Treatment 1 Follow-up 2</td>
<td>Baseline 2</td>
<td>Treatment 2</td>
<td>Treatment 2 Follow-up 1</td>
</tr>
<tr>
<td>Time Point</td>
<td>Day 1</td>
<td>Day 3+1 from V1</td>
<td>Day 7+1 from V2</td>
<td>Day 6+2 from V3</td>
<td>Day 3+1 from V4</td>
<td>Day 7+1 from V5</td>
</tr>
<tr>
<td>Estimated Visit Duration</td>
<td>2.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
<td>1.5 hours</td>
</tr>
<tr>
<td>Unworn Lens (if applicable)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Dispensing Criteria</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Instructions</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Dispense Test Article</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Schedule Follow-up</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Final Evaluation</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
### 7.2. Detailed Study Procedures

**VISIT 1**

Subjects must report to the visit wearing their habitual contact lenses, to accurately assess baseline CLUE performance. If the subject is not wearing their lenses they must be rescheduled.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Statement of Informed Consent</td>
<td>Each subject must read, understand, and sign the Statement of Informed Consent before being enrolled into the study. The Principal Investigator or his/her designee conducting the informed consent discussion must also sign the consent form. Note: The subject must be provided a signed copy of this document.</td>
</tr>
<tr>
<td>1.2</td>
<td>Demographics</td>
<td>Record the subject’s date of birth, gender, race and ethnicity.</td>
</tr>
<tr>
<td>1.3</td>
<td>Medical History and Concomitant Medications</td>
<td>Questions regarding the subjects’ medical history and concomitant medications.</td>
</tr>
<tr>
<td>1.4</td>
<td>Habitual Lenses</td>
<td>Record the brand of their current contact lens, lens parameters, modality (i.e. daily wear, extended wear, etc.) and cleaning regiment.</td>
</tr>
<tr>
<td>1.5</td>
<td>Contact Lens History</td>
<td>Record the subject’s correction type (i.e. monovision, multifocal, sphere with readers, etc.).</td>
</tr>
<tr>
<td>1.6</td>
<td>Wear Time</td>
<td>Record the subjects wear time and comfortable wear time with their habitual contact lenses.</td>
</tr>
<tr>
<td>1.7</td>
<td>Eligibility after Screening</td>
<td>All responses to Screening Inclusion Criteria questions must be answered “yes” and all responses to Exclusion Criteria must be answered “no” for the subject to be considered eligible.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.8</td>
<td>Baseline Questionnaire and CLDEQ-8 Questionnaire</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of their habitual lenses using the PRO questions and the Contact Lens Dry Eye Questionnaire</td>
</tr>
<tr>
<td>1.9</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>1.10</td>
<td>Entrance Distance and Near Visual Acuity</td>
<td>Record the distance and near Snellen visual acuity (OD, OS, and OU) to the nearest letter with their habitual contact lens correction in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
<tr>
<td>1.11</td>
<td>Lens Removal</td>
<td>Have the subject remove their habitual lenses and store in an approved solution.</td>
</tr>
<tr>
<td>1.12</td>
<td>Pupillometry</td>
<td>The pupil measurements will be performed OD and OS under bright illumination (7.3-7.9 EV) and dark illumination (≤0 EV) using a Neuroptic Pupillometer or similar instrument. The room illuminance will be measured for each condition using the Sekonic lightmeter or similar instrument.</td>
</tr>
<tr>
<td>1.13</td>
<td>Keratometry</td>
<td>Keratometry will be performed OD and OS recording the steep and flat dioptic power, corresponding meridians and clarity of mires.</td>
</tr>
<tr>
<td>1.14</td>
<td>Subjective Sphero-cylindrical Refraction</td>
<td>An optimal, binocular balanced distance sphero-cylindrical refraction will be performed. Record the refraction and distance visual acuity to the nearest letter. <strong>Note:</strong> Best distance visual acuity with sphero-cylindrical refraction must be at least 20/20⁴ in each eye for the subject to enroll in the study.</td>
</tr>
<tr>
<td>1.15</td>
<td>Near ADD Determination</td>
<td>The near reading addition will be determined using the binocular crossed cylinder technique at 40 cm followed by optimization in a trial frame in step 1.17 below.</td>
</tr>
<tr>
<td>1.16</td>
<td>Ocular Dominance</td>
<td>Determine the distance ocular dominance with the best distance correction in place using a +1.00-blur test. If the results are equivocal use the sighting dominance test to determine the dominant eye used for the study. Appendix E</td>
</tr>
<tr>
<td>1.17</td>
<td>Add Refinement</td>
<td>Place the BCC result in the trial frame and refine the near prescription with trial lenses (or flippers) under binocular conditions.</td>
</tr>
<tr>
<td>1.18</td>
<td>Near Visual Acuity</td>
<td>Using the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm. Record the near visual acuity OD, OS and OU at 40 cm.</td>
</tr>
</tbody>
</table>
1.19 Biomicroscopy
FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.

For the conjunctival redness 0.5 unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments.

If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.

1.20 Eligibility after Baseline
All responses to Inclusion Criteria questions must be answered “yes” and all responses to Exclusion Criteria questions must be answered “no” for the subject to be considered eligible.

Determine whether the subject is eligible to participate in the study based on the examination findings. If so, proceed to lens fitting. If not, complete the final evaluation and discharge the subject.

---

Visit 1: Treatment 1 Lens Fitting

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.21</td>
<td>Randomization ID</td>
<td>Record the Randomization ID per the random scheme.</td>
</tr>
<tr>
<td>1.22</td>
<td>Lens Selection</td>
<td>Select the lens pair and power based on the randomization table and appropriate fitting guide for each eye. Record the test lens parameters (power and lot number). Appendix G or H Fitting Guides</td>
</tr>
<tr>
<td>1.23</td>
<td>Lens Insertion</td>
<td>The Investigator or the subject inserts the study lenses. Record the time of lens insertion. Check for lens damage under the slit lamp before proceeding with lens settling. Replace damaged lenses if applicable. Worn, damaged lenses must be saved in saline and a product complaint form completed.</td>
</tr>
<tr>
<td>1.24</td>
<td>Lens Settling</td>
<td>Allow the study lenses to settle for a minimum of 10 minutes.</td>
</tr>
<tr>
<td>1.25</td>
<td>Visual Satisfaction</td>
<td>Determine if the subject’s vision is acceptable with the lenses. Allow the subject to look</td>
</tr>
<tr>
<td>Section</td>
<td>Procedure/Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>1.26</td>
<td><strong>Distance and Near Visual Acuity</strong>&lt;br&gt;Measure the distance and near visual acuity OD, OS and OU. Record the results. <strong>Note:</strong> Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the near visual acuity.</td>
<td></td>
</tr>
<tr>
<td>1.27</td>
<td><strong>Over-refraction</strong>&lt;br&gt;Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results.&lt;br&gt;The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.</td>
<td></td>
</tr>
<tr>
<td>1.28</td>
<td><strong>Lens Fit Assessment</strong>&lt;br&gt;Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test). The subject will not proceed to wear the lenses if any of the following is observed:&lt;br&gt;- presence of limbal exposure (appearance of clear cornea) in any gaze&lt;br&gt;- presence of edge lift&lt;br&gt;- presence of unacceptable movement (excessive or insufficient) in all three movement categories (primary gaze, upgaze, and push-up).&lt;br&gt;&lt;em&gt;If either lens is deemed unacceptable, the subject will be discontinued from the study. Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.&lt;/em&gt;</td>
<td></td>
</tr>
<tr>
<td>1.29</td>
<td><strong>Modifications</strong>&lt;br&gt;If the subject's vision is unacceptable for at least one distance or the Investigator determines that the visual acuity or over-refraction are not acceptable then a lens modification must be made. Up to two attempts at modification are allowed.</td>
<td></td>
</tr>
</tbody>
</table>

Appendix G or H Fitting Guides
<table>
<thead>
<tr>
<th></th>
<th></th>
<th>permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type. Follow the appropriate fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted. If modifications are required steps 1.22-1.28 will be repeated for each modification.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.30</td>
<td>PRO Post-Fit Questionnaire</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.</td>
</tr>
<tr>
<td>1.31</td>
<td>Exit Distance and Near Visual Acuity</td>
<td>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Note:</strong> The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</td>
</tr>
<tr>
<td>1.32</td>
<td>Dispensing Criteria</td>
<td>The lenses will be dispensed for 2-4 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Distance Snellen acuity equal to or better than 20/30 OU</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Subject must indicate that the vision is acceptable.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Subject must indicate that the comfort of the lenses is acceptable.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lenses must have an acceptable general lens fit.</td>
</tr>
<tr>
<td>1.33</td>
<td>Subject Instructions</td>
<td>Instruct the Subject the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The lenses will be worn on a daily wear basis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• A new lens will be opened and worn each day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Instruct the subject to bring back all Unworn study lenses</td>
</tr>
</tbody>
</table>
|   |   | • Instruct the subject no cleaning or
disinfecting solutions will be used. If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.

- Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.
- Subjects will be instructed to wear their glasses when not wearing the study lenses.
- A patient instruction booklet will be provided.

**Note:** In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.

| 1.34 | Schedule Follow-up Visit | The subject will be scheduled to return for their follow-up appointment in 3±1 days. |

**Note:** To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.

**VISIT 2**

The subjects must present to Visit 2 wearing the study lenses.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Adverse Events, Medical History and Concomitant Medications Review</td>
<td>Review the subject’s concomitant medications and record any changes from the previous study visit. Record any adverse events or medical history changes from the previous study visit.</td>
</tr>
<tr>
<td>2.2</td>
<td>Wearing Time</td>
<td>Record the average wearing time and comfortable wearing time.</td>
</tr>
<tr>
<td>2.3</td>
<td>Compliance</td>
<td>Confirm compliance with the prescribed wear schedule.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Note:</strong> Subjects must have worn lenses for at least 6 hours per day. To be counted as a day of wear at this visit the subject must have worn the study lenses for 6 hours prior to the visit.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>2.4.</td>
<td>PRO and CLDEQ-8 Questionnaires</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire and the Contact Lens Dry Eye Questionnaire</td>
</tr>
<tr>
<td>2.5.</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>2.6.</td>
<td>Visual Satisfaction</td>
<td>Record whether the subjects distance and near vision with the lenses is acceptable.</td>
</tr>
<tr>
<td>2.7.</td>
<td>Distance and Near Entrance Visual Acuity</td>
<td>Measure the distance and near visual acuity OD, OS and OU to the nearest letter. Record the results. <strong>Note:</strong> Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity.</td>
</tr>
<tr>
<td>2.8.</td>
<td>Distance Over-refraction and Distance Visual Acuity</td>
<td>Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results and distance visual acuity OD and OS. The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.</td>
</tr>
<tr>
<td>2.9.</td>
<td>Determination of Lens Optimization</td>
<td>If the subjects vision is unacceptable for at least one distance or the Investigator determines that the visual acuity or over-refraction are not acceptable then a lens modification must be made. Up to two attempts at modification are permitted if necessary, to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that lens type. Follow the appropriate fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.</td>
</tr>
<tr>
<td>Section</td>
<td>Procedure</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 2.10. Lens Fit Assessment | Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).  
- The subject should not proceed to wear the lenses if any of the following is observed:  
- presence of limbal exposure (appearance of clear cornea) in any gaze  
- presence of edge lift  
- presence of unacceptable movement (excessive or insufficient) in all three movement categories (primary gaze, upgaze, and push-up). | If either lens is deemed unacceptable, the subject will be discontinued from the study. Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form. |
| 2.11. Collection of unworn lenses | Collect unworn lenses returned by the subject when lens power has been optimized. | Note: If lens power was not changed allow the subject to use the unworn lenses dispensed at Visit 1 and dispense enough lenses of the same power to last the subject until their next visit. |
| 2.12. Lens Removal | The optimized study lenses will be removed and discarded. | |
| 2.13. Biomicroscopy | FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.  
For the conjunctival redness, 0.5 unit increments will be used in the grading.  
Corneal Staining Assessment will be graded in 1.0 increments. | If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled. |
| 2.14. Insertion of Study Lenses | Dispense the subject new lenses that match the Distance and ADD power of the lenses that were removed in Step 2.12 above.  
Dispense enough lenses to last the subject |
<table>
<thead>
<tr>
<th>2.15.</th>
<th>PRO Questionnaire</th>
<th>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.16.</td>
<td>Exit Distance and Near Visual Acuity</td>
<td>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
</tbody>
</table>
| 2.17. | Dispensing Criteria | The lenses will be dispensed for 6-8 days.  
- Distance Snellen acuity equal to or better than 20/30 OU  
- Subject must indicate that the vision is acceptable.  
- Subject must indicate that the comfort of the lenses is acceptable.  
- Lenses must have an acceptable general lens fit. |
| 2.18. | Subject Instructions | Instruct the Subject the following:  
- The lenses will be worn on a daily wear basis.  
- Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.  
- A new lens will be opened and worn each day.  
- Instruct the subject to bring back all Unworn study lenses  
- Instruct the subject no cleaning or disinfecting solutions will be used. If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.  
- Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.  
- Subjects will be instructed to wear their glasses when not wearing the study lenses. |
**VISIT 3**

The subjects must present to Visit 3 wearing the study lenses.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Adverse Events, Medical History and Concomitant Medications Review</td>
<td>Review the subject's concomitant medications and record any changes from the previous study visit. Record any adverse events or medical history changes from the previous study visit.</td>
</tr>
<tr>
<td>3.2</td>
<td>Wearing Time</td>
<td>Record the average wearing time and comfortable wearing time.</td>
</tr>
</tbody>
</table>
| 3.3  | Compliance | Confirm compliance with the prescribed wear schedule.  

**Note:** Subjects must have worn lenses for at least 6 hours per day. To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.

| 3.4  | PRO and CLDEQ-8 Questionnaires | The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire and the Contact Lens Dry Eye Questionnaire. |
| 3.5  | Subject Reported Ocular Symptoms | Subjects will respond to a verbal open-ended symptoms questionnaire. |
| 3.6 | Visual Satisfaction | Record whether the subjects distance and near vision with the lenses is acceptable. |
| 3.7 | Distance and Near Entrance Visual Acuity | Measure the distance and near visual acuity OD, OS and OU to the nearest letter. Record the results.  
**Note:** Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity |
| 3.8 | Binocular Over-refraction | Perform a binocular over-refraction and record the OD and OS results and distance visual acuity.  
**Note:** No lens changes are allowed based on the over-refraction. |
| 3.9 | Lens Fit Assessment | Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).  
- The subject should not proceed to wear the lenses if any of the following is observed:  
- presence of limbal exposure (appearance of clear cornea) in any gaze  
- presence of edge lift  
- presence of unacceptable movement (excessive or insufficient) in all three movement categories (primary gaze, upgaze, and push-up).  
*If either lens is deemed unacceptable, the subject will be discontinued from the study. Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.* |
| 3.10 | Visual Performance | Visual performance will be recorded OD, OS and OU for the following:  
**Distance, Bright Illuminance**  
ETDRS Charts 3M-HC#1, HC#2, HC#3 and LC#1, LC#2 and LC#3  
**Near, Bright Illuminance**  
Reduced Guillon-Poling charts  
High Contrast and Low Contrast Intermediate (64cm) and Near (40cm). |
<table>
<thead>
<tr>
<th>3.11</th>
<th>Collection of unworn lenses</th>
<th>Collect unworn lenses returned by the subject.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.12</td>
<td>Lens Removal</td>
<td>The study lenses can be removed, and saved in sterile saline in labeled glass vials</td>
</tr>
<tr>
<td>3.13</td>
<td>Biomicroscopy</td>
<td>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility. For the conjunctival redness 0.5 unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.</td>
</tr>
<tr>
<td>3.14</td>
<td>Exit Distance and Near Visual Acuity</td>
<td>Distance and near Snellen visual acuity will be measured for each eye with the subject’s habitual correction in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
<tr>
<td>3.15</td>
<td>Wash-out Period</td>
<td>Subject will complete a 6±2 days wash-out period during which they can wear their habitual contact lenses or glasses.</td>
</tr>
</tbody>
</table>
Visit 4

Subjects must report to this visit wearing their habitual contact lenses, to accurately assess baseline CLUE performance. If the subject is not wearing their lenses they must be rescheduled.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Adverse Events, Medical History and Concomitant Medications Review</td>
<td>Review the subject’s concomitant medications and record any changes from the previous study visit.</td>
</tr>
<tr>
<td>4.2</td>
<td>Baseline Questionnaire and CLDEQ-8 Questionnaire</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of their habitual lenses using the PRO questions and the Contact Lens Dry Eye Questionnaire</td>
</tr>
<tr>
<td>4.3</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>4.4</td>
<td>Entrance Distance and Near Visual Acuity</td>
<td>Record the distance and near Snellen visual acuity (OD, OS, and OU) to the nearest letter with their habitual contact lens correction in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
<tr>
<td>4.5</td>
<td>Lens Removal</td>
<td>Have the subject remove their habitual lenses and store in an approved solution.</td>
</tr>
<tr>
<td>4.6</td>
<td>Biomicroscopy</td>
<td>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility. For the conjunctival redness (0-3) 0.5 unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.</td>
</tr>
<tr>
<td>4.7</td>
<td>Continuance</td>
<td>Determine whether the subject is eligible to continue in the study based on the examination findings.</td>
</tr>
<tr>
<td>Step</td>
<td>Procedure</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>4.8</td>
<td>Lens Selection</td>
<td>Select the lens pair and power based on the randomization table and appropriate fitting guide for each eye. Record the test lens parameters (power and lot number).</td>
</tr>
<tr>
<td>4.9</td>
<td>Lens Insertion</td>
<td>The Investigator or the subject inserts the study lenses. Record the time of lens insertion. Check for lens damage under the slit lamp before proceeding with lens settling. Replace damaged lenses if applicable. Worn, damaged lenses must be saved in saline and a product complaint form completed.</td>
</tr>
<tr>
<td>4.10</td>
<td>Lens Settling</td>
<td>Allow the study lenses to settle for a minimum of 10 minutes.</td>
</tr>
<tr>
<td>4.11</td>
<td>Visual Satisfaction</td>
<td>Determine if the subject's vision is acceptable with the lenses. Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.</td>
</tr>
<tr>
<td>4.12</td>
<td>Distance and Near Visual Acuity</td>
<td>Measure the distance and near visual acuity OD, OS and OU. Record the results.</td>
</tr>
<tr>
<td></td>
<td>Note: Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity</td>
<td></td>
</tr>
<tr>
<td>4.13</td>
<td>Over-refraction</td>
<td>Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results. The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.</td>
</tr>
<tr>
<td>4.14</td>
<td>Lens Fit Assessment</td>
<td>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test). The subject will not proceed to wear the lenses if any of the following is observed: • presence of limbal exposure (appearance of clear cornea) in any gaze</td>
</tr>
<tr>
<td>4.15</td>
<td>Modifications</td>
<td>If the subjects vision is unacceptable for at least one distance or the Investigator determines that the visual acuity or over-refraction are not acceptable then a lens modification must be made. Up to two attempts at modification are permitted if necessary, to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type. Follow the appropriate fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted. If modifications are required steps 4.8 to 4.14 will be repeated for each modification.</td>
</tr>
<tr>
<td>4.16</td>
<td>PRO Post-Fit Questionnaire</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of their study lenses using the PRO questionnaire.</td>
</tr>
<tr>
<td>4.17</td>
<td>Exit Distance and Near Visual Acuity</td>
<td>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU. <strong>Note:</strong> The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</td>
</tr>
<tr>
<td>4.18</td>
<td>Dispensing Criteria</td>
<td>The lenses will be dispensed for 2-4 days. - Distance Snellen acuity equal to or better than 20/30 OU - Subject must indicate that the vision is acceptable.</td>
</tr>
</tbody>
</table>
| 4.19 | Subject Instructions | Instruct the Subject the following:

- The lenses will be worn on a daily wear basis.
- Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.
- A new lens will be opened and worn each day.
- Instruct the subject to bring back all Unworn study lenses
- Instruct the subject no cleaning or disinfecting solutions will be used. If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.
- Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.
- Subjects will be instructed to wear their glasses when not wearing the study lenses.

**Note:** In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.

| 4.20 | Schedule Follow-up Visit | The subject will be scheduled to return for their follow-up appointment in 3±1 days.

**Note:** To count the follow-up visit as a day of
VISIT 5

The subjects must present to Visit 5 wearing the study lenses.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1</td>
<td>Adverse Events, Medical History and Concomitant Medications Review</td>
<td>Review the subject’s concomitant medications and record any changes from the previous study visit. Record any adverse events or medical history changes from the previous study visit.</td>
</tr>
<tr>
<td>5.2</td>
<td>Wearing Time</td>
<td>Record the average wearing time and comfortable wearing time.</td>
</tr>
<tr>
<td>5.3</td>
<td>Compliance</td>
<td>Confirm compliance with the prescribed wear schedule. <strong>Note:</strong> Subjects must have worn lenses for at least 6 hours per day. To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</td>
</tr>
<tr>
<td>5.4</td>
<td>PRO and CLDEQ-8 Questionnaires</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire and the Contact Lens Dry Eye Questionnaire</td>
</tr>
<tr>
<td>5.5</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>5.6</td>
<td>Visual Satisfaction</td>
<td>Record whether the subjects distance and near vision with the lenses is acceptable.</td>
</tr>
<tr>
<td>5.7</td>
<td>Distance and Near Entrance Visual Acuity</td>
<td>Measure the distance and near visual acuity OD, OS and OU to the nearest letter with the study lenses in place. Record the results. <strong>Note:</strong> Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity.</td>
</tr>
<tr>
<td>5.8</td>
<td>Distance Over-refraction and Distance Visual Acuity</td>
<td>Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results and distance visual acuity OD and OS.</td>
</tr>
<tr>
<td>5.9</td>
<td><strong>Determination of Lens Optimization</strong></td>
<td>If the subjects vision is unacceptable for at least one distance or the Investigator determines that the visual acuity or over-refraction are not acceptable then a lens modification must be made. Up to two attempts at modification are permitted if necessary, to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type. Follow the appropriate fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.</td>
</tr>
</tbody>
</table>
| 5.10 | **Lens Fit Assessment** | Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).
- The subject should not proceed to wear the lenses if any of the following is observed:
- presence of limbal exposure (appearance of clear cornea) in any gaze
- presence of edge lift
- presence of unacceptable movement (excessive or insufficient) in all three movement categories (primary gaze, upgaze, and push-up).

*If either lens is deemed unacceptable, the subject will be discontinued from the study. Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.* |
<p>| 5.11 | <strong>Collection of unworn lenses</strong> | Collect unworn lenses returned by the subject when lens power has been optimized. <strong>Note:</strong> If lens power was not changed allow the subject to use the unworn lenses dispensed at Visit 4 and dispense enough lenses of the same power to last the subject until their next visit. |
| 5.12 | <strong>Lens Removal</strong> | The optimized study lenses will be removed and discarded. |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.13</td>
<td>Biomicroscopy</td>
<td>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility. For the conjunctival redness unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.</td>
</tr>
<tr>
<td>5.14</td>
<td>Insertion of Study Lenses</td>
<td>Dispense the subject new lenses that match the Distance and ADD power of the lenses that were removed in Step 5.12 above. Dispense enough lenses to last the subject until their next visit.</td>
</tr>
<tr>
<td>5.15</td>
<td>PRO Questionnaire</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of their study lenses using the PRO questionnaire.</td>
</tr>
<tr>
<td>5.16</td>
<td>Exit Distance and Near Visual Acuity</td>
<td>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</td>
</tr>
<tr>
<td>5.17</td>
<td>Dispensing Criteria</td>
<td>The lenses will be dispensed for 6-8 days. - Distance Snellen acuity equal to or better than 20/30 OU - Subject must indicate that the vision is acceptable. - Subject must indicate that the comfort of the lenses is acceptable. - Lenses must have an acceptable general lens fit.</td>
</tr>
<tr>
<td>5.18</td>
<td>Subject Instructions</td>
<td>Instruct the subject the following: - The lenses will be worn on a daily wear basis. - Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</td>
</tr>
</tbody>
</table>
• A new lens will be opened and worn each day.
• Instruct the subject to bring back all Unworn study lenses
• Instruct the subject no cleaning or disinfecting solutions will be used. If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.
• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.
• Subjects will be instructed to wear their glasses when not wearing the study lenses.

Note: In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.

5.19 Schedule Follow-up Visit

The subject will be scheduled to return for their follow-up appointment in 7±1 days.

VISIT 6

The subjects must present to Visit 6 wearing the study lenses.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>Adverse Events, Medical History and Concomitant Medications Review</td>
<td>Review the subject's concomitant medications and record any changes from the previous study visit. Record any adverse events or medical history changes from the previous study visit.</td>
</tr>
<tr>
<td>6.2</td>
<td>Wearing Time</td>
<td>Record the average wearing time and comfortable wearing time.</td>
</tr>
<tr>
<td>6.3</td>
<td>Compliance</td>
<td>Confirm compliance with the prescribed wear schedule.</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>6.4</td>
<td>PRO and CLDEQ-8 Questionnaires</td>
<td>The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire and the Contact Lens Dry Eye Questionnaire.</td>
</tr>
<tr>
<td>6.5</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>6.6</td>
<td>Visual Satisfaction</td>
<td>Record whether the subjects distance and near vision with the lenses is acceptable.</td>
</tr>
<tr>
<td>6.7</td>
<td>Distance and Near Entrance Visual Acuity</td>
<td>Measure the distance and near visual acuity OD, OS and OU to the nearest letter. Record the results. <strong>Note:</strong> Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the near visual acuity.</td>
</tr>
<tr>
<td>6.8</td>
<td>Binocular Over-refraction</td>
<td>Perform a binocular over-refraction and record the OD and OS results and distance visual acuity. <strong>Note:</strong> No lens changes are allowed based on the over-refraction.</td>
</tr>
</tbody>
</table>
| 6.9     | Lens Fit Assessment | Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).  
- The subject should not proceed to wear the lenses if any of the following is observed:  
  - presence of limbal exposure (appearance of clear cornea) in any gaze  
  - presence of edge lift  
  - presence of unacceptable movement (excessive or insufficient) in all three movement categories (primary gaze, upgaze, and push-up).  
  
*If either lens is deemed unacceptable, the subject will be discontinued from the study.* |
<table>
<thead>
<tr>
<th>6.10</th>
<th>Visual Performance</th>
<th>Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visual performance will be recorded OD, OS and OU for the following:</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Distance, Bright Illuminance</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ETDRS Charts 3M-HC#1, HC#2, HC#3 and LC#1, LC#2 and LC#3</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Near, Bright Illuminance</strong></td>
<td>Reduced Guillon-Poling charts High Contrast and Low Contrast Intermediate (64cm) and Near (40cm).</td>
</tr>
<tr>
<td></td>
<td><strong>Distance, Dim Illuminance</strong></td>
<td>(with <strong>Distance goggles</strong>) ETDRS Charts 3M-HC#4, HC#5, HC#6</td>
</tr>
<tr>
<td></td>
<td><strong>Near, Dim Illuminance</strong></td>
<td>(with <strong>Near goggles</strong>) Reduced Guillon-Poling charts High Contrast Intermediate (64 cm) and Near (40 cm).</td>
</tr>
<tr>
<td></td>
<td><strong>Note:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The room illuminance must be between 7.3 and 7.9 EV.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Distance, HC-1 Chart luminance Acceptable EV Range 10.5-10.7.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Guillon-Poling, Near Chart luminance Acceptable EV Range 10.8-11.1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Do not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)</td>
<td></td>
</tr>
<tr>
<td>6.11</td>
<td>Collection of unworn lenses</td>
<td>Collect unworn lenses returned by the subject.</td>
</tr>
<tr>
<td>6.12</td>
<td>Lens Removal</td>
<td>The study lenses can be removed, and saved in sterile saline in labeled glass vials</td>
</tr>
<tr>
<td>6.13</td>
<td>Biomicroscopy</td>
<td>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.</td>
</tr>
<tr>
<td></td>
<td>For the conjunctival redness 0.5 unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments.</td>
<td></td>
</tr>
</tbody>
</table>
If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.

**FINAL EVALUATION**

The final evaluation will ordinarily take place immediately following the last scheduled follow-up visit per the study protocol. It may also take place at any point the subject discontinues the study or is terminated from the study.

**Note:** If the subject is a screen-failure and a refraction and/or biomicroscopy procedure has just been performed, you may intentionally blank out these forms at the Final Evaluation in EDC.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>F.1</td>
<td>Subjective sphero-cylindrical Refraction</td>
<td>Perform subjective sphero-cylindrical refraction with a phoropter and record the best corrected distance visual acuity to the nearest letter (OD, OS, OU).</td>
</tr>
<tr>
<td>F.2</td>
<td>Final Exam Form</td>
<td>Indicate if the subject completed the study successfully. If subject discontinued from the study indicate the reason.</td>
</tr>
</tbody>
</table>

7.3. **Unscheduled Visits**

If, during the investigation, a subject requires an unscheduled visit to the clinical site, the following information will be collected at a minimum:

- Chief complaint prompting the visit. If the reason is an adverse event, the applicable eCRF for the adverse event must be completed and subject record completed as appropriate
- Date and time of the visit and all procedures completed at the unscheduled visit
- Review of adverse event and concomitant medications
- Documentation of any test article dispensed or collected from the subject, if applicable
- Slit lamp findings (using the Slit Lamp Classification Scale)

If the Investigator withdraws a subject from the study, the final study visit case report forms must be completed indicating the reason(s) why the subject was withdrawn. The subject record must be completed documenting the date and primary reason for withdrawal and the study CRA notified.

Any ocular and non-ocular Adverse Events that are ongoing at the time of the study visit will be followed by the Investigator, within licensure, until they have resolved, returned to pre-treatment status, stabilized, or been satisfactorily explained. If further treatment i.e., beyond licensure is required, the subject will be referred to the appropriate health care provider.
The following information will be collected during an unscheduled visit.

<table>
<thead>
<tr>
<th>Step</th>
<th>Procedure</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.1</td>
<td>Chief Complaints</td>
<td>Record the subject’s chief complaints for reasons for the unscheduled visit</td>
</tr>
<tr>
<td>U.2</td>
<td>Change of Medical History and Concomitant Medications</td>
<td>Questions regarding the change of subjects’ medical history and concomitant medications.</td>
</tr>
<tr>
<td>U.3</td>
<td>Subject Reported Ocular Symptoms</td>
<td>Subjects will respond to a verbal open-ended symptoms questionnaire.</td>
</tr>
<tr>
<td>U.4</td>
<td>Entrance VA</td>
<td>Record the entrance distance and near visual acuity (OD, OS and OU) to the nearest letter.</td>
</tr>
<tr>
<td>U.5</td>
<td>Subjective Sphero-cylindrical Refraction</td>
<td>An optimal, binocular balanced distance sphero-cylindrical refraction will be performed. Record the refraction and distance visual acuity to the nearest letter.</td>
</tr>
<tr>
<td>U.6</td>
<td>Biomicroscopy</td>
<td>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility. For the conjunctival redness, 0.5 unit increments will be used in the grading. Corneal Staining Assessment will be graded in 1.0 increments. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.</td>
</tr>
<tr>
<td>U.7</td>
<td>Lens Dispensing</td>
<td>Additional lenses may be dispensed if the subject loses, tears, or runs out of lenses.</td>
</tr>
<tr>
<td>U.8</td>
<td>Exit Visual Acuity</td>
<td>Record the subject’s exit distance and near visual acuity (OD, OS and OU) to the nearest letter.</td>
</tr>
</tbody>
</table>

7.4. Laboratory Procedures

Not Applicable
8. SUBJECTS COMPLETION/WITHDRAWAL

8.1. Completion Criteria

Subjects are considered to have completed the study if they:
- provided informed consent;
- they are eligible;
- have not withdrawn/discontinued for any reason described in Section 8.2;
- Complete all study visits

8.2. Withdrawal/Discontinuation from the Study

A subject will be withdrawn from the study for any of the following reasons:
- Subject death during the study period
- Subject withdrawal of consent
- Subject not compliant to protocol
- Subject lost to follow-up
- Subject no longer meets eligibility criteria (e.g. the subject becomes pregnant)
- Subject develops significant or serious adverse events causing discontinuation of study lens wear
- Subjects who have experienced a Corneal Infiltrative Event (CIE)
- Investigator’s clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment)
- Subject not compliant with study lens wear schedule
- Subject not successfully dispensed due to lack of efficacy and safety including poor vision, poor comfort or unacceptable fit

For discontinued subjects, the Investigator will:
- Complete the current visit (scheduled or unscheduled)
- Complete the Final Evaluation, indicating the reason that the subject was discontinued from the study
- Record the spherocylindrical refraction with best corrected distance visual acuity
- Collect used test article(s) (worn or brought to the visit) from the subject and discard them, unless otherwise stated in Section 7.2
- Collect all unused test article(s) from the subject

An additional subject may be enrolled if a subject discontinues from the study prematurely.

In cases where a subject is lost to follow-up, every possible effort must be made to contact the subject and determine the reason for discontinuation/withdrawal. The measures taken to follow up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt.
9. **PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION**

Concomitant medications will be documented during screening and updated during the study. Disallowed medications for this study include: Any ocular medications except for rewetting drops. Concomitant therapies that are disallowed include: Any therapies that may contraindicate lens wear.

10. **DEVIATIONS FROM THE PROTOCOL**

Investigator will notify study sponsor upon identification of a protocol deviation. Major protocol deviations must be reported to the sponsor within 24 hours after discovery of the protocol deviation. The Investigator will report deviations per IRB/IEC requirements. All deviations will be tracked and corrective actions implemented as appropriate.

If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, the Investigator may implement the deviation immediately without notification to the sponsor. Within 24 hours after the implemented deviation, the Investigator must notify and provide the rationale to the Sponsor and, as required, the IEC/IRB.

11. **STUDY TERMINATION**

If more than 2 subjects in the investigational soft contact lens group develop serious expected (e.g., definite or probable MK) or unexpected device related adverse events, the study will be suspended. Upon review and consultation with IRB, and JJVC safety review committee, the study may be terminated.

The occurrence of one or more Unanticipated Serious Adverse Device Effect (USADE), or any SAE where the relationship to study agent cannot be ruled out, may result in stopping further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled.

The Sponsor will determine when a study will be stopped. The Principal Investigator always has the discretion to initiate stopping the study based on patient safety or if information indicates the study’s results are compromised.

JJVC reserves the right to terminate the study at any time for any reason. Additionally, the IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by the Principal Investigator at the individual clinical site due to specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is determined that an adverse event presents an unreasonable risk, the investigation, or that part of the investigation presenting the risk, will be terminated, as soon as possible.

Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.

12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS

A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of test articles after they have been released for clinical trial use.

Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints:

- Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient Reported Outcomes (PRO)”.
- Clinical test articles that are stored improperly or damaged after receipt at the investigational site.
- Lens replacements that occur due to drops/fall-outs.
- Damage deemed by clinicians or clinical staff to be caused by handling by the user, and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject.

Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notifications or when an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.

Upon receipt of the EDC notification, the COM/CRA will contact the study site to collect additional information which will include:

- Date the complaint was received/recorded in the EDC System (Date of Sponsor Awareness)
- Who received the complaint
- Study number
- Clinical site information (contact name, site ID, telephone number)
- Lot number(s)
- Unique Subject Identifier(s)
- Indication of who first observed complaint (site personnel or subject)
- OD/OS indication, along with whether or not the lens was inserted
- Any related AE number if applicable
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.)
• Eye Care Provider objective (slit lamp) findings if applicable
• Confirmation of product availability for return (and tracking information, if available), or rationale if product is not available for return

Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or trained site personnel will follow Section 13 of this protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also applies and will be executed in parallel.

In some cases, a PQC form may be generated in EDC by the site in error. In this event, the PQC forms will be marked “Intentionally Left Blank” or “ILB”. Justification for ILB must be documented.

13. ADVERSE EVENTS

13.1. Definitions and Classifications

Adverse Event (AE) – An AE is any untoward (unwanted) medical occurrence in a patient or clinical investigation subject administered a test article, study treatment or study procedure whether caused by the test article, study treatment or procedure. An AE can therefore be any unfavorable or unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of the test article, study treatment, or study procedure whether or not related to the test article, study treatment, or study procedure.

An AE includes any condition (including a pre-existing condition) that:
1. Was not present prior to the study, but appeared or reappeared following initiation of the study
2. Was present prior to the study, but worsened during the study. This would include any condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states
3. Pregnancy must be documented as an adverse event and must be reported to the clinical monitor and to the Sponsor immediately upon learning of the event

Serious Adverse Event (SAE) – An SAE is any untoward medical occurrence that:
• Results in death
• Is life threatening
• Requires in-patient hospitalization or prolongation of existing hospitalization
• Results in persistent or significant disability/incapacity (e.g., a sight threatening event, a significant persistent or permanent change, impairment, damage, or disruption to the subject’s body)
• Is a congenital anomaly/birth defect, or
• Requires intervention to prevent permanent damage (the use of the test article resulting in a condition which requires medical or surgical intervention to preclude permanent impairment of the body structure or a body function). Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in the above definition.

Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:

• Microbial Keratitis (MK)
• Iritis (including cells in the anterior chamber)
• Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater
• Central Corneal Opacity
• Central Corneal Neovascularization
• Uveitis
• Endophthalmitis
• Hypopyon
• Hyphemia
• Penetration of Bowman’s Membrane
• Persistent Epithelial Defect
• Limbal cell Damage leading to Conjunctivalization

**Significant Adverse Events** – Those events that are usually symptomatic and warrant discontinuation (temporary or permanent) of the test article (excluding Serious Adverse Events).

Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but not limited to the following:

• Contact Lens Induced Peripheral Ulcer (CLPU)
• Significant Infiltrative Events (SIE)
• Superior Epithelial Arcuate Lesions (SEALs)
• Any Temporary Loss of >2 Lines of BSCVA
• Other Grade 3 or higher corneal findings, such as abrasions or edema
• Non-contact lens related corneal events - e.g. Epidemic Keratoconjunctivitis (EKC)
• Asymptomatic Corneal Scar
• Any corneal event which necessitates temporary lens discontinuation >2 weeks

**Non-Significant Adverse Events** – Those conditions that are usually asymptomatic and usually do not warrant discontinuation (temporary or permanent) of the test article. However, the Investigator may choose to treat as a precautionary measure.

Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, but not limited to the following:
• Non-significant Infiltrative Event (NSIE)
• Contact Lens Papillary Conjunctivitis (CLPC)
• Superficial Punctate Keratitis (SPK)
• Conjunctivitis: Bacterial, Viral, Allergic
• Blepharitis
• Meibomianitis
• Contact Dermatitis
• Localized Allergic Reactions
• Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary lens discontinuation < 2 weeks

Adverse Device Effect (ADE) – A sub-set of AEs, and include only those adverse events that are cause by or related to the investigational device.

Unanticipated Adverse Device Effect (UADE) – Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, the test article, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.

13.2. Assessing Adverse Events

In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include:
• Seriousness/Classifications (see definition in Section 13.1)
• Causality or Relatedness – i.e. the relationship between the test article, study treatment or study procedures and the adverse event (not related; doubtful; possible; probable; very likely - see definition in Section 13.2.1)
• Adverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse event (mild; moderate; severe for all events - see definition in Section 13.2.2).
• Outcome – Not Recovered or Not Resolved; Recovering or Resolving; Recovered or Resolved with Sequelae; Recovered or Resolved; Death Related to Adverse Event; Unknown
• Actions Taken – None; temporarily discontinued; permanently discontinued; other action taken

13.2.1 Causality Assessment

Causality Assessment – A determination of the relationship between an adverse event and the test article, study treatment, or study procedure. The test article, study treatment or study procedure relationship for each adverse event shall be determined by the Investigator using these explanations:
• Not Related- An adverse event that is not related to the use of the test article, study treatment or study procedures.
• Doubtful – An adverse event for which an alternative explanation is more likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is unlikely.

• Possible – An adverse event that might be due to the use of the test article, or to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded.

• Probable – An adverse event that might be due to the use of the test article. The relationship in time is suggestive (e.g. confirmed by de-challenge). An alternative explanation is less likely, e.g. concomitant treatment or concomitant disease(s).

• Very Likely – An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by de-challenge and re-challenge.

13.2.2 Severity Assessment

Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event as determined by the Investigator or reported to him/her by the subject. The assessment of severity is made irrespective of test article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale:

• Mild – Event is noticeable to the subject, but is easily tolerated and does not interfere with the subject’s daily activities

• Moderate – Event is bothersome, possible requiring additional therapy, and may interfere with the subject’s daily activities

• Severe – Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with the subject’s daily activities

13.3. Documentation and Follow-Up of Adverse Events

The recording and documenting of adverse events (ocular and non-ocular) begins when the subjects are exposed to the test article, study treatment or study procedure. Adverse events reported before the use of test article, start of study treatment, or study procedures will be recorded as medical history. However, if the condition deteriorates at any time during the study it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse events at the discretion of the Investigator.

Upon finding an adverse event, the Principal Investigator will document the condition in the subject record and in the eCRFs. He/she will complete the Adverse Event /eCRF.

Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for “serious adverse events” shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.
It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such documentation will include the following:

- Adverse event (diagnosis not symptom)
- Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.)
- Date the clinical site was notified
- Date and time of onset
- Date and time of resolution
- Adverse event classification, severity, and relationship to test articles, as applicable
- Treatment regimen instituted, including concomitant medications prescribed, in accordance with applicable licensing requirements
- Any referral to another health care provider if needed
- Outcome, ocular damage (if any)
- Likely etiology
- Best corrected visual acuity at the discovery of the event and upon conclusion of the event

In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment /eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.

Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationship to the Test Article shall also be clearly documented.

Subjects who present with an adverse event shall be followed by the Investigator, within licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved. If further treatment beyond licensure is required, the patient will be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether or not a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be the responsibility of the Investigator to record the reason for discontinuation. The Investigator will also document the adverse event appropriately and complete the Adverse Event /eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or study procedures, as of the final study visit date should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by the Investigator.

13.4. Reporting Adverse Events

The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone as soon as possible and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery for any non-significant adverse event.
In addition, a written report will be submitted by the Principal Investigator to the IEC/IRB according to their requirements (Section 13.4.2). The report will comment whether or not the adverse event was considered to be related to the test article, study treatment or study procedures.

13.4.1 Reporting Adverse Events to Sponsor

Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring during the study period as soon as possible by e-mail, fax, or telephone, but no later than 24 hours following discovery of the event. The Investigator is obligated to pursue and obtain information requested by the Sponsor in addition to that information reported on the eCRF. All subjects experiencing a serious/significant adverse event must be followed up and all outcomes must be reported.

When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received. The Sponsor and study monitor should be notified prior to unmasking the test articles.

In the event of a serious/significant adverse event, the Investigator must:
- Notify the Sponsor immediately
- Obtain and maintain in the subject’s records all pertinent medical information and medical judgment for colleagues who assisted in the treatment and follow-up of the subject
- Provide the Sponsor with a complete case history which includes a statement as to whether the event was or was not related to the use of the test article
- Notify the IEC/IRB as required by the IEC/IRB reporting procedure according to national regulations

Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later than 24 hours after the Investigator first learns of the effect. This report is in addition to the immediate notification mentioned above.

The Sponsor must conduct an evaluation of the UADE and must report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after the Sponsor first receives notification of the effect.

Non-Serious Adverse Events
All non-serious adverse events, including non-serious adverse device effects, will be reported to the sponsor by the Investigator no later than 2 days from discovery.

13.4.2 Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set
forth by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth by their local governing Health Authorities.

The Sponsor will report applicable Adverse Events to the local health authorities according the written guidelines, including reporting timelines.

13.5. Event of Special Interest
None

13.6. Reporting of Pregnancy
Subjects reporting pregnancy (by self-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once discontinued, pregnant participants and their fetuses will not be monitored for study related purposes. At the Investigator’s discretion, the study participant may be followed by the Investigator through delivery. However, this data will not be collected as part of the clinical study database. Pregnant participants are not discontinued from contact lens or solution related studies for safety concerns, but due to general concerns relating to pregnancy and contact lens use. Specifically, pregnant women are discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.

14. STATISTICAL METHODS

14.1. General Considerations
All data summaries and statistical analyses will be performed using the SAS software Version 9.4 (SAS Institute, Cary, NC). Throughout the analysis of data, the results for each subject/eye will be used when available for summarization and statistical analysis. Unscheduled visits will be summarized separately and will be excluded from the statistical analysis.

Summary tables (Descriptive statistics and/or frequency tables) will be provided for all baseline variables, efficacy variables and safety variables as appropriate. Continuous variables will be summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will be provided for categorical data.

Summaries will be presented by study lens type and will be performed separately by completion status. All analyses will be conducted on per-protocol population (see section 14.3).

14.2. Sample Size Justification
A total of approximately 80 eligible subjects will be enrolled into the study at this site and at least 60 subjects will complete this study. This is a pilot study for assessing the test articles. As such, the sample size calculation was not based on any power analysis with regard to the primary endpoint. The collected data will be used to design future trials.
14.3. Analysis Populations

Safety Population:
All subjects who were administered any test article excluding subjects who drop out prior to administering any test article. At least one observation should be recorded.

Per-Protocol Population:
All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hard lock (Per-Protocol Population). Justification of excluding subjects with protocol deviations in the per-protocol population set will be documented in a memo to file.

Intent-to-Treat (ITT) Population:
All randomized subjects regardless of actual treatment and subsequent withdrawal from study or deviation from protocol. At least one observation should be recorded.

14.4. Level of Statistical Significance
All planned analysis for this study will be conducted with an overall type I error rate of 5%. No adjustment for multiple comparisons will be conducted unless specified otherwise. This is a pilot study and all the hypotheses are exploratory in nature.

14.5. Primary Analysis
Primary efficacy analysis:

Visual Performance:
Near and distance binocular, high luminance, high contrast visual performance on logMAR scale will be analyzed separately using a linear mixed model to test for the difference between the study lens systems. Each model will include the experimental design factors: sequence of lens wear, lens wearing period and lens type as fixed effects. Other baseline characteristics known of importance such as age, gender, and/or add power will be included as fixed covariates when appropriate. The covariance between residual errors from the same subject across lens wearing periods will be selected based on the finite-sample corrected Akaike’s Information Criterion (Keselman et al. 1998). Covariance structures considered may include: Homogenous compound symmetry (CS) and Unstructured covariance structure (UN). The structure that returns the lowest Akaike Information Criteria Corrected (AICC) will be selected as the structure that best fit the data.

Comparisons will be carried out using 95% confidence intervals constructed of least squared means (LSM) from the linear mixed models. Statistical superiority will be concluded if the upper limit of the confidence intervals of the test lens is below $+0.01$ logMAR for distance and $+0.17$ for near.
14.6. Secondary Analysis

CLUE Vision Score:
Overall quality of vision scores will be analyzed using a linear mixed model adjusting for baseline values as fixed covariates. The model will include the experimental design factors: sequence of lens wear, period, lens type as fixed effects. The covariance between residual errors from the same subject across lens wearing periods will be selected based on the finite-sample corrected Akaike’s Information Criterion (Keselman et al. 1998). Covariance structures considered may include: Homogenous compound symmetry (CS) and Unstructured covariance structure (UN). The structure that returns the lowest Akaike Information Criteria Corrected (AICC) will be selected as the structure that best fit the data.

Comparisons will be carried out using 95% confidence intervals constructed of least squared means (LSM) from the linear mixed models. Statistical superiority will be concluded if the lower limit of the confidence intervals of the test lens is above 32 points.

In all models, the Kenward and Roger method (Kenward and Roger, 1997) will be used for the calculation of the denominator of degrees of freedom.

14.7. Other Exploratory Analyses

Not applicable.

14.8. Interim Analysis

Not Applicable

14.9. Procedure for Handling Missing Data and Drop-Outs

Missing or spurious values will not be imputed. The count of missing values will be included in the summary tables and listings.

Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. Past clinical trials don’t provide the evidence that subject dropout is systematic or not-at-random. To evaluate the impact of missing data, sensitivity analysis will be conducted using multiple imputation methods if the proportion of subject dropout is greater than the 15%. The SAS/STAT procedures PROC MI and PROC MIANALYZE will be utilized with a parametric regression method used to make at least 5 imputations.

14.10. Procedure for Reporting Deviations from Statistical Plan

The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate from these analysis methods. If for any reason a change is made, the change will be documented in the study report along with a justification for the change.
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING

15.1. Electronic Case Report Form/Data Collection

The data for this study will be captured on electronic case report forms (eCRFs) using an BioClinica Express version 5.5 EDC system. An authorized data originator will enter study data into the eCRFs using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and sent to JJVC for analysis.

External Data Sources for this study include: Not Applicable

The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator. The sponsor or sponsor’s representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.

Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data will be transmitted from the clinical site to a secure central database as forms are completed or updated, ensuring information accuracy, security, and confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all the study data. The IPP must be retained in the study files as a certified copy of the source data for the study.

The content and structure of the eCRFs are compliant with ISO14155:2011.

15.2. Subject Record

At a minimum, subject record should be available for the following:
- subject identification
- eligibility
- study identification
- study discussion
- provision of and date of informed consent
- visit dates
- results of safety and efficacy parameters as required by the protocol
- a record of all adverse events
- follow-up of adverse events
- medical history and concomitant medication
- test article receipt/dispensing/return records
- date of study completion
- reason for early discontinuation of test article or withdrawal from the study, if applicable
The subject record is the eCRF or an external record. The author of an entry in the subject record must be identifiable. The first point of entry is the source record.

Adverse event notes must be reviewed and initialed by the Investigator.

16. DATA MANAGEMENT

16.1. Access to Source Data/Document

The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and regulatory inspection(s) by providing direct access to source data/documents. Should the clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be contacted and notified in writing within 24 hours.

16.2. Confidentiality of Information

Information concerning the investigational product and patent application processes, scientific data or other pertinent information is confidential and remains the property of JJVC. The Investigator may use this information for the purposes of the study only. It is understood by the Investigator that JJVC will use information developed in this clinical study about the development of the investigational product and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete test results and all data developed during this study to the Sponsor.

16.3. Data Quality Assurance

Steps will be taken to ensure the accuracy and reliability of data, include the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are familiar with the protocol and all study-specific procedures and have appropriate knowledge of the study article.

Training on case report form completion will be provided to clinical site personnel before the start of the study. The Sponsor will review case report forms for accuracy and completeness remotely during the conduct of the study, during monitoring visits, and after transmission to data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.

Quality Assurance representatives from JJVC may visit clinical sites to review data produced during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for monitoring and auditing by JJVC and for inspection by local and regulatory authorities.
17. **MONITORING**

The study monitors will maintain close contact with the Principal Investigator and the Investigator's designated clinical site personnel. The monitor's responsibilities will include:

- Ensuring that the investigation is being conducted according to the protocol, any subsequent amendments, and regulatory requirements are maintained
- Ensuring the rights and wellbeing of subjects are protected
- Ensuring adequate resources, including facilities, laboratories, equipment, and qualified clinical site personnel
- Ensuring that protocol deviations are documented with corrective action plans, as applicable
- Ensuring that the clinical site has sufficient test article and supplies
- Clarifying questions regarding the study
- Resolving study issues or problems that may arise
- Reviewing of study records and source documentation verification in accordance with the monitoring plan

18. **ETHICAL AND REGULATORY ASPECTS**

18.1. **Study-Specific Design Considerations**

Potential subjects will be fully informed of the risks and requirements of the study and, during the study, subjects will be given any new information that may affect their decision to continue participation. Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and potential adverse events of the study, and provide their consent voluntarily will be enrolled.

18.2. **Investigator Responsibility**

The Principal Investigator is responsible for ensuring that the clinical study is performed in accordance with the signed agreement, the investigational plan, Section 4 of the ICH E6 guidelines on Good Clinical Practice (GCP), and applicable regulatory requirements. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles of the Declaration of Helsinki 64th WMA General Assembly 2013 and that the clinical study data are credible. The Investigator must maintain clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical Practice (GCP), and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB)

Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of the following documents (where applicable):

- Final protocol and, if applicable, amendments
- Sponsor-approved informed consent form (and any other written materials to be provided to the subjects)
- Investigator's Brochure (or equivalent information) and amendments
- Sponsor-approved subject recruitment materials
- Information on compensation for study-related injuries or payment to subjects for participation in the study
- Investigator's curriculum vitae, clinical licenses, or equivalent information (unless not required, as documented by IEC/IRB)
- Information regarding funding, name of the Sponsor, institutional affiliations, other potential conflicts of interest, and incentives for subjects
- Any other documents that the IEC/IRB requests to fulfill its obligation

This study will be undertaken only after IEC/IRB has given full approval of the final protocol, amendments (if any), the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of this approval. This approval letter must be dated and must clearly identify the documents being approved.

During the study the Investigator (or Sponsor when applicable) will send the following documents to the IEC/IRB for their review and approval, where appropriate:

- Protocol amendments
- Revision(s) to informed consent form and any other written materials to be provided to subjects
- If applicable, new or revised subject recruitment materials approved by the Sponsor
- Revisions to compensation for study-related injuries or payment to subjects for participation in the study
- Investigator's Brochure amendments or new edition(s)
- Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB)
- Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB's requirements
- New information that may adversely affect the safety of the subjects or the conduct of the study
- Major protocol deviations as required by the IEC/IRB
- Report of deaths of subjects under the Investigator's care
- Notification if a new Investigator is responsible for the study at the clinical site
- Any other requirements of the IEC/IRB

For protocol amendments that increase subject risk, the amendment and applicable informed consent form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.

At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this notification must be retained at the clinical site and a copy provided to the CRO or Sponsor as applicable.

18.4. Informed Consent

Each subject must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The consent form that is used must be approved by both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and Sponsor policy.

Before entry into the study, the Investigator or an authorized member of the clinical site personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any discomfort it may entail. Subjects will be informed that their participation is voluntary and that they may withdraw consent to participate at any time.

The subject will be given sufficient time to read the informed consent form and the opportunity to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by means of the subject's dated signature. After having obtained the consent, a copy of the informed consent form must be given to the subject.

18.5. Privacy of Personal Data

The collection, processing and disclosure of personal data and medical information related to the Study Subject, and personal data related to Principal Investigator and any clinical site personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to compliance with the Data Protection Act of 1998 and other applicable personal data protection and security laws and regulations. Appropriate measures will be employed to safeguard these data, to maintain the confidentiality of the person's related health and medical information, to properly inform the concerned persons about the collection and processing of their personal data, to grant them reasonable access to their personal data and to prevent access by unauthorized persons.

All information obtained during the course of the investigation will be regarded as confidential. All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor's personnel and IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.
The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product(s) used in this study.

These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations. The Sponsor ensures that the personal data will be:

- processed fairly and lawfully
- collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes
- adequate, relevant, and not excessive in relation to said purposes
- accurate and, where necessary, kept current

Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries.

The subject has the right to request through the Investigator access to his personal data and the right to request rectification of any data that are not correct or complete. Reasonable steps should be taken to respond to such a request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws and regulations.

Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential.

19. STUDY RECORD RETENTION

In compliance with the ICH/GCP guidelines, the Investigator/Institution will maintain all CRFs and all subject records that support the data collected from each subject, as well as all study documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical Trial, and all study documents as specified by the applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.

Essential documents must be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents will be retained for a longer period if required by the applicable regulatory requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained.

If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping the study records, custody must be transferred to a person who will...
accept the responsibility. The Sponsor must be notified in writing of the name and address of the new custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor.

If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports. If the Investigator has a question regarding retention of study records, he/she should contact JJVC.

20. FINANCIAL CONSIDERATIONS

Remuneration for study services and expenses will be set forth in detail in the Investigator’s Research Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC management representative prior to study initiation.

Case Report Forms will be completed in real time according to the study procedures specified in the study protocol. Case Report Forms should be completed and reviewed and signed as applicable by the Investigator within 3 days of visit completion. Data queries must be addressed with complete responses within 3 days of generation. JJVC reserves the right to withhold remuneration until these activities are addressed.

JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as:
- Continuing an ineligible subject in the study
- Scheduling a study visit outside the subject’s acceptable visit range

21. PUBLICATION

This study will be registered on ClinicalTrials.gov by the Sponsor

22. REFERENCES

APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)
APPENDIX B: PATIENT INSTRUCTION GUIDE

Provided separately.
MONOVISION FITTING GUIDELINES

1. Patient Selection

a. Monovision Needs Assessment

For a good prognosis, the patient should have adequately corrected distance and near visual acuity in each eye. The amблиопic patient or the patient with significant astigmatism (more than 1.00 diopter) in one eye may not be a good candidate for monovision with the Bausch + Lomb Bioclear® ONEday (prescription A) Soft (Hydrophilic) Contact Lens or Bausch + Lomb Biofinity® ONEday for Astigmatism (prescription A) Soft (Hydrophilic) Contact Lens. Occupational and environmental visual demands should be considered. If the patient requires critical visual (visual safety and stereopsis) it should be determined whether this patient can function adequately with monovision. Contact lens wear may not be optimal for such activities as:

1. Visually demanding situations such as operating potentially dangerous machinery or performing other potentially hazardous activities;
2. Driving automobiles (e.g., at night);
3. Patients who cannot pass their state driver’s license requirements with monovision correction should be advised not to drive with this correction; OR may require that additional overcorrection be prescribed.

b. Patient Education

At no function equally well with monovision correction. Patients may not perform as well as with corrective lenses with monovision correction should be advised not to drive with this correction; OR may require that additional overcorrection be prescribed.

2. Eye Selection

Generally, the non-dominant eye is corrected for near vision. The following test for eye dominance can be used:

a. Cover Test Preferences Determination Methods

Method 1: Determine which eye is losing 5° of visual field.

Method 2: Determine which eye corrects the better with a mood inducer.

b. Relative Lens Method

For anisotropic corrections, it is generally best to correct the more hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.

3. Special Fitting Considerations

Unilateral monovision

There are circumstances where only one correction is required. As an example, an emmetropic presbyopic patient who requires a +1.75 dipter add would have a +1.75 dipter add on one eye and the other eye left with no lenses.

A presbyopic patient requiring a +1.50 dipter add in both eyes would have a +1.50 dipter add in both eyes, with +1.00 dipter add in the left eye.

CR-5860, v3.0 Amendment 2.0

Page 112 of 215

CARE FOR A STICKING (NONMOVING) LENS

If the lens sticks (stops moving), the patient should be instructed to lubricate or rewetting solution in each eye. The patient should be instructed to use only water, saline, or other recommended solutions. The patient should be instructed to use the eye care professional if the lens does not begin to move upon blinking after several applications of the solution, and to return for an examination. The patient should be referred for an appointment with the eye care professional.

EMERGENCIES

In the event of a severe reaction, immediate medical attention should be sought. In addition to administering topical anesthetic drops, treatment may include systemic antihistamines and corticosteroids.

REPORTING OF ADVERSE REACTIONS

At all severe adverse reactions and severe reactions observed in patients wearing Bausch & Lomb Bioclear® ONEday (prescription A) Soft (Hydrophilic) Contact Lenses, Bausch & Lomb Biofinity® ONEday for Astigmatism (prescription A) Soft (Hydrophilic) Contact Lenses or Bausch & Lomb Biofinity® ONEday for Astigmatism (prescription A) Soft (Hydrophilic) Contact Lenses, or experienced with the lenses, should be reported to:

Bausch & Lomb Incorporated
1600 North Goodman Street
Rochester, New York 14607

Toll Free Telephone Number
In the Continental U.S., Atlanta, Hawaii
1-800-563-5340

In California
(888) 435-5000 (Option 1: English, Option 2: French)

HOW SUPPLIED

Each single lens is supplied in a plastic package containing a sterile buffered saline solution with preservative and a lens case. Each lens is packaged with the manufacturer's name, the strength, the number of lenses, the lens power, and an expiration date.

JVC CONFIDENTIAL
DAILIES TOTAL1® and DAILIES TOTAL1® Multifocal (deflacao A) Soft Contact Lenses for Daily Disposable Wear

CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.

PRODUCT DESCRIPTION
DAILIES TOTAL1® and DAILIES TOTAL1® Multifocal (deflacao A) soft contact lenses are made from a lens material that is 30% water and 67% (deflacao A) polyvinyl chloride containing hydrophilic plastic additives. The core lens material containing 52% water transitions through a water gradient to a hydrophilic surface layer that exceeds 60% water. Lenses contain the color additive copper phthalocyanine, a light blue tint, which makes them easier to see when handling.

Lens Properties
- Refractive Index: 1.42
- Light Transmittance: 80% (690 nm, -1.00D)
- Oxygen Permeability (Dk): 140 x 10^{-10} cm² (ml O²)/(ml/mm Hg)
- Diameter: measured at 35°C
  - (Intrinsic: Cle Cylindrical cornea)
- Water Content: 50% by weight of nonvolatiles
- Surface Water Content: ≥ 60%

Lens Parameters Available:
- DAILIES TOTAL1® (deflacao A) spherical
  - DIA: 14.1 mm
  - CT: 0.09 mm ≤ 3.00D (slices with power)
  - Base Curve: 8.6 mm
  - Powers: -6.00 ≤ D ≤ -0.00 (0.25D steps) -6.00 ≤ D ≤ -12.00 (0.25D steps) -6.00 ≤ D ≤ +6.00 (0.25D steps)

DAILIES TOTAL1® Multifocal (deflacao A)
- DIA: 14.1 mm
- CT: 0.09 mm ≤ 3.00D (slices with power)
- Base Curve: 8.6 mm
- Powers: -6.00 ≤ D ≤ -10.00 (0.25D steps) 0.00 ≤ D ≤ +6.00 (0.25D steps)

NOTE: Hereafter, DAILIES TOTAL1® spherical lenses and DAILIES TOTAL1® Multifocal lenses are referred to as deflacao A contact lenses unless product distinction is necessary.

WARNINGS
Advisory patients of the following warnings pertaining to contact lens wear:
- Problems with contact lenses and lens care products could result in serious injury or loss of vision. It is essential that patients follow their eye care professional’s directions and all labeling instructions for proper use of lenses and lens care products.
- Serious eye problems, including corneal disease, can develop rapidly and lead to loss of vision.
- Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical study results have shown that the risk of serious adverse reactions is increased when contact lenses are worn overnight.
- Staphylococcus has shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than non-smokers.
- If a patient experiences discomfort, foreign body sensation, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly consult his or her eye care professional. It is recommended that contact lens wearers see their eye care professional regularly as directed.

PRECAUTIONS
Prevent damage to the eyes or to the contact lenses, the following precautions should be taken:
- Special Precautions for the Eye Care Professional:
  - Due to the small number of patients evaluated in the clinical investigation of lenses, all refractive powers, design configurations, and lens parameters available in the lens material are not evaluated in significant numbers. Consequently when selecting an appropriate lens design and configuration, the eye care professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, central and peripheral thickness, and optic zone diameter. The potential impact of these factors on the patient’s ocular health should be carefully weighed against the patient’s need for refractive correction; therefore the continuing ocular health of the patient and lens performance on the eye should be carefully evaluated on initial dispensing and monitored on an ongoing basis by the prescribing eyecare professional.
  - Fluorocel, a yellow dye, should not be used while the lenses are on the patient’s eyes. The lenses absorb this dye and become discolored. When Fluorocel is used, the eyes should be flushed thoroughly with sterile saline solution that is recommended for eye use prior to inserting lenses. Avoid dispensing saline from an aerosol can directly into the eye.
  - Patients who wear contact lenses to correct myopia may not achieve the best possible corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
  - Before leaving the eye care professional’s office, the patient should be able to remove their lenses or should have someone else available who can remove their lenses for them.
  - Eye care professionals should instruct the patient to remove the lenses immediately if the eye becomes red or irritated.
  - Routine eye examinations are necessary to help ensure the continued health of the patient’s eyes. Eye care professionals should make arrangements with the patient for appropriate follow-up visits.
- Alcon recommends that patients see their eye care professional once each year, or more often, as recommended by the eye care professional.
- Diabetics may have reduced corneal sensitivity and thus are more prone to corneal injury and do not heal as quickly or completely as non-diabetics.
- Visual changes or losses in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

Eye Care Professionals should carefully instruct patients about the following safety precautions:
- Be sure that before leaving the eye care professional’s office the patient is able to properly remove lenses or have someone else available to remove them.
- Good hygiene habits help promote safe and comfortable lens wear. Always wash, rinse, and thoroughly dry hands with a lint-free towel before handling lenses.
- REMOVE A LENS IMMEDIATELY if an eye becomes red or irritated.
- Always handle lenses carefully; never use tweezers or other sharp objects such as fingernails to remove lenses from the lens container unless specifically indicated for that use.
- Do not use if blister package is damaged or not sealed completely. This may result in product contamination which can lead to a serious eye infection.
- Ensure that the correct lens for each eye is available. Gently slide each lens from its package prior to opening. Remove the lens from the blister pack by carefully pressing the lens onto the palm of your clean hand. Ensure the lens is right side up. Inspect the lens prior to insertion. Do not insert damaged lenses.
- To Insert lenses:
  - Wash and rinse hands thoroughly and dry completely with a clean, lint-free towel before handling lenses.
  - Place a lens on the tip of your clean and dry right or left index finger, place the middle finger of the same hand close to lower eyelid and pull down the lower eyelid.
  - Use the fingers of the other hand to lift the upper eyelid.
  - Place the lens directly on the eye (cornea) and gently roll finger away from the lens.
  - Look down and slowly remove the hand, releasing the lower lid.
  - Look straight ahead and slowly remove the other hand, releasing the upper lid.
  - Blink gently.
- To Remove lenses:
  - Wash and rinse hands thoroughly and dry completely with a clean, lint free towel before handling lenses.
  - Make sure hands are clean and completely dry.
  - Blink several times.
  - While looking up, slide the lens down onto the white part of the eye.
  - Remove the lens by pinching gently between the thumb and forefinger. Do not pinch the eye tissue.
  - If the lens is difficult to grasp, dry fingers once more and try again. Do not use wearing drops in this instance.
- If a lens denatures on the eye, it may be possible to recenter it by:
  - Closing the eye and massaging the lens into place, or
  - Looking in the direction of the lens and tilting gently, or
  - Gently pushing the off-centered lens onto the cornea with light finger pressure on the edge of the upper or lower eyelid.
- If a lens tears in the eye it will feel uncomfortable. Ask the wearer to remove the lens and start over.
  - If the lens fails to come off, ask the wearer to remove the lens and start over.
- If a lens falls out of the eye and remains in the eye, it may be possible to remove the lens, provided the lens pieces are removed by pinching it as for normal lens removal, carefully avoiding pinching the eye tissue. If the lens pieces do not easily remove easily, take the remaining lens pieces and return to the patient, if they can be used, giving them to the patient.

Lens Warening Precautions:
- Patients should never exceed the prescribed wearing schedule regardless of how comfortable the lenses feel. Doing so may increase the risk of adverse effects.
- The lens should be worn on the eye at all times. If the lens gets out of position (e.g., if it moves off the pupil), instruct the patient to remove the lens and follow the recommended directions in the Care for a Sticking Lens section. If non-removal of the lens continues, the patient should be instructed to consult their eye care professional immediately.

Page 11 of 215
JVC CONFIDENTIAL
• The eye care professional should be consulted when wearing lenses during water sports or water-related activities.

Exposure to water or other non-stereile liquids while wearing contact lenses in activities such as swimming, water skiing, and hot tubs may increase the risk of ocular infection, including but not limited to Keratoconus and Anterior Keratitis.

• Never allow contact lenses to come into contact with non-stereile liquids (including tap water and saliva) as microbial contamination can occur, which may lead to permanent eye damage.

• Eye irritation, infection, or lens damage may result if cosmetics, lotion, soap, cream, hair spray, deodorant, aerosol products or foreign particles come in contact with lenses.

• Environmental factors, smoke, and vapors should be avoided in order to reduce the chance of lens contamination or physical injury to the cornea.

• Lenses should be disposed of each day upon removal from the eye.

• Discard any lens which has become cloudy or damaged. Replace with a sterile, fresh, new lens.

• Note the correct lens power for each eye to prevent getting them mixed up.

• Always carry spare lenses with you or have back-up spectacles available.

• Do not share lenses with anyone as this may spread microorganisms which could result in serious eye health problems.

• Do not use lenses beyond their expiration date.

Other Topics to Discuss with Patients:

• Periodic eye examinations are extremely important for contact lens wearers. Schedule and conduct appropriate follow-up examinations to determine ocular response. Alcon recommends that patients see their eye care professional once every six months, or as recommended by the eye care professional.

• Certain medications may cause dryness of the eye, increased lens awareness, lens intolerance, and blurred vision or visual changes. These medications include antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, and those for nicotine addiction. Careful patients using such medications accordingly and prescriber proper preservative measure.

• Vascular changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Careful patients accordingly.

Who Should Know that the Patient is Wearing Contact Lenses:

• Patients should inform their health care providers that they are wearing contact lenses.

• Patients should inform their employers that they are wearing contact lenses. Some jobs may require the use of eye protection equipment or may require that contact lenses not be worn.

It is strongly recommended that patients be provided with a copy of the DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal Contact Lenses (DEFINITION) Patient Information Booklet from Alcon and understand its contents prior to dispensing the lenses.

ADVERSE EFFECTS

Patients should be instructed to check eyes regularly to make sure they look well, feel comfortable and vision is clear. Potentially serious complications are usually accompanied by one or more of the following signs or symptoms:

• Moderate to severe eye pain not relieved by removing the lens.

• Foreign body sensation.

• Invasive watering or other eye sensations including mucus conjunctival discharge

• Redness of the eyes

• Photophobia (light sensitivity)

• Burning, stinging or itching or other path associated with the eyes.

• Contact lens is loose when compared to the lens was first placed on the eye

• Poor visual acuity (reduced sharpness of vision)

• Skewed vision, contours or halo around objects

• Feeling of dryness

WHAT TO DO IF A PROBLEM OCCURS

Patients should be instructed that if any of the above signs or symptoms are noticed, he or she should:

• IMMEDIATELY REMOVE THE LENSES.

• If the discomfort or problem occurs, discard the lens and replace it with a new one.

• If the discomfort or problem continues after removing the lens(ey) or upon insertion of a new lens, IMMEDIATELY remove the lens(ey) and contact the eye care professional for identification of the problem and prompt treatment to avoid serious eye damage.

• The patient should be informed that a serious condition such as corneal abrasion, infection, corneal vascularization, or lirra may be present, and may progress rapidly. Lens surfer reactions such as abrasions, blebbedness, and gradually cornification must be managed and treated carefully to avoid serious complications.

• Additionally, contact lenses may be associated with corneal changes that require management of discontinuation or restriction of wear. These include but are not limited to toxic or generalized corneal edema, epithelial microcysts, epithelial erosion, infiltrates, neovascularization, endothelial polygonization, tear film instability, conjunctival injection or leaks.

ADVERSE EFFECT REPORTING

If a patient experiences any serious adverse effects associated with the use of DAILIES TOTAL1* brand (DEFINITION) A contact lenses, please notify Alcon Medical Safety at 1-800-707-9790.

FITTING GUIDE AND PATIENT BOOKLET

Conventional methods of fitting contact lenses apply to DAILIES A contact lenses. For a detailed description of the fitting techniques, refer to the DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal Contact Lenses (DEFINITION) A Professional Fitting and Information Guide. Both the presentation Fitting guide and a patient instruction booklet are available free of charge from Alcon Laboratories, Inc.

DAILIES TOTAL1* South America
Fort Worth, TX, USA 76124-2099
1-800-241-6999

LENS WEAR & REPLACEMENT SCHEDULES

DAILY WEAR (less than 24 hours, while awake):

• To avoid tendency of the daily patient to wear the lenses initially, strongly the importance of adhering to a pre-wearing schedule. Normal daily wear of lenses assumes a maximum of 6 hours of non lens wear per 24 hour period.

It may be advisable for patients who have never worn contact lenses previously to be given a wearing schedule that gradually increases the wearing time over a few days. This allows a gradual adaptation of the ocular tissues to contact lens wear.

• The maximum daily wearing time should be determined by the eye care professional based upon the patient's physiological eye condition because individual responses to contact lenses vary. There may be a tendency for patients to overwear the lenses initially. The eye care professional should stress the importance of adhering to the initial maximum wearing schedule. Studies have not been conducted to show that different contact lenses are able to wear during sleep. Therefore, patients should be advised to remove their lenses while sleeping. Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24 hour period. Optimum individual wearing schedule will vary.

• Definition A contact lenses are intended to be worn once (daily disposable wear) and then discarded at the end of each wearing period. The patient should be instructed to start the next wearing period with a fresh new lens.

EMERGENCY LENS CARE

Cleaning and disinfection of daily disposable lenses is not recommended. The patient should be reminded to have replacement lenses or back-up spectacles available at all times.

CASE FOR A STICKING LENS

If the lens sticks (plops moving) or begins to dry on the eye, instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens becomes moist before removing the lens. If the lens continues to stick, the patient should IMMEDIATELY consult the eye care professional.

IN OFFICE USE OF TITER LENSES

Eye care professionals should educate contact lenses technicians concerning proper use of trial lenses. Each contact lens is shipped in a blister pack containing phosphate buffered saline solution. Hands should be thoroughly washed and dried and a lubricant towel prior to handling a lens. In order to ensure sterility, the lenses should not be opened until immediately prior to use. For fitting and diagnostic purposes, lenses should be dispensed after a single use and not be re-used from patient to patient.

EMERGENCIES

The patient should be informed that if chemicals of any kind, household products, purging solutions, laboratory chemicals, etc. are splashed into the eyes, the patient should:

• Flush eyes immediately with tep water or fresh saline solution and immediately contact the eye care professional or visit a hospital emergency room without delay.

HOW SUPPLIED

Each lens is packaged in a foil-sealed plastic container containing phosphate-buffered saline solution with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyvinylpyrrolidone and polyvinylpyrrolidone. The package is sterilized with ethylene oxide gas. The package is marked with the base curve, diameter, diopter power and ADD power (multifocal lenses), manufacturing lot number and expiration date.

The following may appear on the labels or cartons:

- Symbol/Signal Word/Description
- DANGER: Content of this device may be harmful if swallowed or inhaled.
- SYMBOL: Steam sterilized
- HOW SUPPLIED: Use by date (Expiration date)
- ADD (ADD) POC: Do not need POC: Do not need POC: Multiple package is damaged
- Contact lens is: Example of a letter and number code (English)
- EAD: Diameter
- EC: Base curve
- PWR: Power
- D (D) (ADD power)
- ADD: Addition power
- CO: Corneal curve
- CCA: Cylindrical curve amount
- Lazio: Cylindrical Axis
- See product instructions
- Authorized Representative
- European Community

Manufacturer
- Alcon Laboratories, Inc.
- 6951 South Freeway
- Fort Worth, TX, USA 76134-2099
- www.Alcon.com
- 1-800-241-6999
- March 2016
- W90038292-0416

*See back of insert

1 Check for actual product availability as additional parameters may be introduced over time.
APPENDIX D: PRESBYOPIC SYMPTOMS QUESTIONNAIRE

Presbyopic Symptoms Questionnaire

1. 

☐

☐

☐

☐

☐
APPENDIX H: DAILIES TOTAL 1\(^{st}\) MULTIFOCAL FITTING GUIDE
Professional Fitting and Information Guide

DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) Soft Contact Lenses For Single-Use, Daily Disposable Wear

Water Gradient One-Day Contact Lenses

Rx only

CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.

Alcon®
a Novartis company
### Table of Contents

- **Introduction** ................................................................. 5
- **Product Description** ................................................ 5
  - Lens Properties ................................................... 6
  - Available Lens Parameters ........................................ 6
  - Actions .................................................................. 6
- **Indications (Uses)** .................................................... 6
- **Contraindications, Warnings, Precautions, Adverse Effects** ....... 7
- **Adverse Effect Reporting** ............................................... 7
- **Fitting Guidelines (Spherical Lenses)** .................................. 8
  - Patient Selection .................................................... 8
  - Pre-fitting Examination ........................................... 8
  - Trial Lens Evaluation ............................................... 8
    - Lens Base Curve Selection ..................................... 8
    - Initial Lens Power Selection .................................. 8
    - Lens Fit Assessment ............................................ 9
    - Final Lens Power Determination .............................. 10
- **Fitting Guidelines (Multifocal Lenses)** ................................ 11
  - Pre-Fitting Examination ............................................ 11
  - Patient Selection .................................................... 11
  - Initial Lens Selection ................................................ 13
  - Initial Lens Fitting Evaluation .................................. 14
  - Initial Lens Visual Evaluation .................................... 15
  - Fitting Procedures ................................................... 16
- **Fitting Guidelines (Monovision)** ....................................... 18
  - Patient Selection .................................................... 18
  - Eye Selection ........................................................ 18
  - Special Fitting Considerations .................................... 19
  - Near Add Determination ............................................ 20
  - Trial Lens Fitting ................................................... 20
  - Adaptation ........................................................... 20
  - Other Suggestions ................................................... 21
- **Dispensing Visit** ......................................................... 21
  - Follow-Up Examinations ............................................ 23
  - Follow-up Examination Procedures ................................ 23
- **Lens Handling Hints** .................................................... 23
  - Lens Insertion ........................................................ 23
  - Lens Removal ........................................................ 24
  - Care for a Sticking Lens ........................................... 24
- **In Office Care of Trial Lenses** .......................................... 25
  - Additional Information ............................................. 25
  - Vertex Distance Conversion Chart .................................. 26
  - Product Package Insert ............................................. 29
Introduction
Thank you for prescribing DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) daily disposable soft contact lenses. The benefits of a high oxygen transmissible and wettable lens material with a state of the art manufacturing process are combined to make DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) lenses. This guide contains important information regarding fitting procedures and aftercare of the DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) contact lens patient.

Daily Disposability:
By eliminating the need for lens care, daily disposable lenses offer your patients a major advancement in wearing convenience. The next time you prescribe lenses consider the health and comfort benefits of beginning each wearing period with a new pair of fresh, sterile lenses that are worn once and then discarded.

LightStream* Lens Technology:
DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) contact lenses are made from a proprietary silicone hydrogel material with a water content of approximately 33% water. The use of process automation, precision glass and quartz molds and photolithographic edge forming help ensure every lens has the same crisp optics, smooth surface finish and consistent edge quality from lens to lens. Delefilcon A contact lenses are produced under strictly controlled process conditions and inspected to exacting quality tolerances. As a result, you can be confident your patients will experience consistent vision, comfort, and ease of handling every day.

PRODUCT DESCRIPTION
DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal soft contact lenses are made from a silicone containing hydrogel that is approximately 33% water and 67% delefilcon A polymer with added phosphatidylcholine. The core lens material containing 33% water transitions through a water gradient to a hydrogel surface layer that exceeds 80% water. This structure enables a silicone hydrogel lens with a water gradient that has:

- Over 80% water at the surface of the lens to mimic the water content of the cornea.
- High level of oxygen transmissibility through the lens.
- Excellent overall comfort.

The lenses contain and release phosphatidylcholine (DMPC), a phospholipid found naturally in the tears. In addition, lenses contain the color additive copper phthalocyanine, a light blue tint which makes them easier to see when handling. The lenses are packaged in strips of 5 individual blisters containing buffered saline with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyacrylamide and poly(acrylamide-acrylic acid).
Lens Properties
- Refractive Index (hydrated): 1.42
- Light Transmittance: ≥ 93% (@610 nm, -1.00D)
- Oxygen Permeability (Dk): 140 x 10^{-11} (cm²/sec)
  (ml O₂/ml x mm Hg), measured at 35°C,
  (Intrinsic Dk - Coulometric method)
- Water Content 33% by weight in normal saline
- Surface Water Content ≥ 80%

Available Lens Parameters1

DAILIES TOTAL1* (delefilcon A)  Spherical contact lenses
- Chord Diameter Available: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers Available: -0.50 to -6.00D (0.25D steps); -6.50 to
  -12.00D (0.50D steps)
  +0.50 to +6.00D (0.25D steps)

DAILIES TOTAL1* Multifocal (delefilcon A)
- Chord Diameter: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers:
  -0.25 to -10.00D (0.25D steps); plano to
  +6.00D (0.25D steps)
  ADD: LO, MED, HI

1Check for actual product availability as additional parameters may be introduced
  over time.

Actions
When hydrated and placed on the cornea delefilcon A soft contact lenses act as a
refracting medium to focus light rays on the retina.

INDICATIONS (USES)
DAILIES TOTAL1* (delefilcon A) spherical soft contact lenses are indicated for
the optical correction of refractive ametropia (myopia and hyperopia) in phakic or
aphakic persons with non-diseased eyes with up to approximately 1.50 diopters
(D) of astigmatism that does not interfere with visual acuity.

DAILIES TOTAL1* Multifocal (delefilcon A) soft contact lenses are indicated
for the optical correction of refractive ametropia (myopia and hyperopia) and/or
presbyopia in phakic or aphanic persons with non-diseased eyes who may require
a reading addition of +3.00 D or less and who may have up to approximately 1.50
diopters (D) of astigmatism that does not interfere with visual acuity.

The lenses are to be prescribed for single use, daily disposable wear. The lenses
are not intended to be cleaned or disinfected and should be discarded after a
single use.
See WARNINGS for information about the relationship between wearing schedule and corneal complications.

CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND ADVERSE EFFECTS
For additional important prescribing and safety information, refer to the Package Insert that is printed in the back of this guide.

ADVERSE EFFECT REPORTING
If a patient experiences any serious adverse effects associated with the use of DAILIES TOTAL1® or DAILIES TOTAL1® Multifocal (deleflicon A) contact lenses, in the USA please contact Alcon Medical Safety at 1-800-757-8780.

FITTING GUIDELINES
Please see the appropriate sections of this booklet that contain guidelines for spherical, multifocal and monovision fitting techniques.
FITTING GUIDELINES (Spherical Lenses)

1. Patient Selection
The patient characteristics necessary to achieve success with DAILIES TOTAL1* (deleflon A) spherical lenses are similar to those for other spherical soft contact lenses. A thorough pre-fitting examination should be conducted to ensure the patient is a suitable candidate for soft contact lens wear.

The following procedures should be followed when fitting DAILIES TOTAL1* (deleflon A) spherical lenses. For additional tips on fitting the monovision patient refer to the section Monovision Fitting Guidelines.

2. Pre-fitting Examination
A pre-fitting examination is necessary to:
- assess the patient’s motivation, physical state and willingness to comply with instructions regarding hygiene and wear schedule
- make ocular measurements for initial contact lens parameter selection
- collect baseline clinical information to which post-fitting examination results can be compared

A pre-fitting examination should include:
- a thorough case history
- a sphero-cylindrical refraction
- keratometry
- tear film assessment
- biomicroscopy

3. Trial Lens Evaluation
A. Lens Base Curve Selection
A well-fitted lens provides good movement, centration and comfort. An optimal fit can be achieved for the vast majority of patients with the single 0.5 mm base curve.

B. Initial Lens Power Selection
The initial power selection should be as close as possible to the patient’s prescription after taking into account spherical equivalent and vertex calculations, if necessary.

Spherical Equivalent Calculation
To determine initial lens power, convert the sphero-cylindrical spectacle Rx to its spherical equivalent as follows:

Spherical Equivalent = Sphere power + 1/2 (Cylinder Power)

Example:
Spectacle Rx: -4.50D -1.00 x 180
Spherical equivalent: -4.50D + (-0.50D) = -5.00D

Vertex Distance Conversion
If the spherical equivalent is greater than ± 4.00D, a vertex distance correction is necessary (see Vertex Distance Conversion Chart) to determine the lens power required at the corneal plane.

Example:
Spectacle Rx: -4.50D -1.00 x 180
Spherical equivalent: -4.50D + (-0.50D) = -5.00D
Vertex compensation: -4.75 (initial lens power)
C. Lens Fit Assessment

Allow the lenses to settle on the eyes for approximately 10 minutes. This allows time for the patient to adapt to the lenses and time for the lens to equilibrate.

Evaluate the fit and movement of the lenses on the eye in primary and up gaze positions. The Push-up Test, as described below, is an additional test of the lens evaluation. The following guidelines will be helpful in fit evaluation:

**Characteristics of a Well-fitted Lens**

A well-fitted DAILIES TOTAL1* (deleflacon A) spherical contact lens satisfies the following criteria:

1. **Good centration and full corneal coverage in all fields of gaze.**
2. **Sufficient lens movement to allow tear exchange under the lens during a blink in primary or upward gaze.**
3. **Satisfactory Push-up Test**
   - This test is a reliable indicator of a good fit. With the patient looking straight ahead, place your index finger on the patient’s lower lid and nudge the edge of the lens upward while observing lens movement. Then pull the lid back down and observe the return of the lens.
   - A well-fitted lens will move freely upward, stopping shortly after passing the limbus and then return freely to its original position.
4. **Good comfort and stable visual response (with over refraction).**

**Characteristics of a Tight (Steep) Lens Fit**

A tight or steep lens fit would display some or all of the following characteristics:

1. Insufficient or no lens movement during a blink in primary or upward gaze.
2. **Unsatisfactory Push-up Test**
   - A tight fitting lens will resist movement. If successfully nudged upward, the lens may remain centered or return slowly to its original position.
3. **Good centration.**
4. **Good comfort.**
5. **Fluctuating vision between blinks.**

**Characteristics of a Loose (Flat) Lens Fit**

A loose lens fit would display some or all of the following characteristics:

1. Reduced comfort, usually accompanied by lower lid sensation.
2. Poor centration with limbal exposure on exaggerated eye movement.
3. **Lens edge standoff.**
4. Excessive lens movement during the blink in primary or upward gaze.
5. **Unsatisfactory Push-up Test**
   - A loose fitting lens will move easily but may remain decentered or slip under the upper lid.
6. **Vision may be blurred after the blink.**

An inverted lens may mimic the characteristics of a loose lens. If any of
the above signs occur remove the lens and check to make sure it is not inverted.

**General Fitting Tips**
- Trial fitting of the individual eye is recommended.
- A well fitting lens will show movement of 0.1 to 0.5 mm.

**D. Final Lens Power Determination**
After the characteristics of a well fitted lens have been satisfied, conduct a spherical over-refraction to determine the proper lens power to be dispensed.

**Example:**
- Diagnostic lens: -4.50
- Over-refraction: -0.25
- Final lens power: -4.75
FITTING GUIDELINES (Multifocal)
The DAILIES TOTAL1 Multifocal (delefilcon A) soft contact lens is a progressive aspheric simultaneous vision soft contact lens, intended to correct presbyopia with or without additional ametropia, available in three ADD powers; low (LO), medium (MED) and high (HI). For each lens the near and intermediate powers are concentrated primarily in the central portion of the optical zone while the distance power is contained in the surrounding portion. The continuous changes in power across the surface of the lens allow patients requiring a reading addition of up to +3.00D to see clearly at far, intermediate, and near distances. Achieving high success with DAILIES TOTAL1 Multifocal (delefilcon A) contact lenses is dependent on several factors, including the patient’s motivation, expectations and visual wearing environment, as well as your skill in optimizing the lens powers to balance binocular performance at distance and near. The information in this guide is designed to provide you with the tools to manage your presbyopic patients through each stage of the process from the initial case history to post-fitting follow-up.

1. **Pre-fitting Examination**
   A pre-fitting examination is necessary to:
   - determine whether a patient is a suitable candidate for DAILIES TOTAL1 Multifocal (delefilcon A) contact lenses
   - make ocular measurements and assessments for initial contact lens parameter selection
   - collect baseline clinical information to which post-fitting examination results can be compared

   A pre-fitting examination should include:
   - a thorough case history
   - detailed assessment of patient’s individual visual demands
   - understanding of patient’s objectives for lens wear and expectations
   - a distance spherocylindrical refraction, near add determination and measurement of pupil diameter
   - keratometry
   - tear assessment
   - biomicroscopy

   Note: The importance of a thorough case history should not be underestimated. The information gained through careful listening and probing will help greatly in satisfying each patient's unique needs.

2. **Patient Selection**
   The eye care professional should weigh several factors when considering patient selection for a DAILIES TOTAL1 Multifocal (delefilcon A) soft contact lens fitting. When fitting a lens intended to correct for presbyopia, it is especially important to evaluate the particular visual needs, objectives, lifestyle and expectations of the individual patient. Prospective candidates may include current contact lens wearers, former wearers, and persons with no previous wear history. For former wearers it is important to determine the cause for discontinuation. There are two general categories of candidates based on anticipated usage: those who seek to wear their lenses as their principal means
of vision correction, and those who wish to integrate the use of their contact lenses with spectacles. The integrative user often seeks to wear their lenses for sports or other occasional activities while reverting to spectacles under poor lighting or otherwise demanding vision conditions. In general, even the part-time user does not require more than a few moments re-adaptation time following an interval of no lens wear. While candidates with greater than 1.00 diopter of refractive error have often been thought of as better candidates than those with low error or emmetropia, this is a generalization that often does not hold true for a given individual. Success is influenced by many factors and the eye care professional is encouraged to offer DAILIES TOTAL1 Multifocal (deleflon A) contact lenses to all interested presbyopic patients who satisfy the standard requirements for soft contact lens wear. To summarize patient selection, the characteristics of "ideal candidates" and those that will be more difficult to fit are listed below:

**Ideal Candidates**

- Refractive cylinder < 1.00D.
- Attainable visual demands that do not depend upon resolving very fine (smaller than 20/20 letters) details at both distance and near for extended periods while wearing DAILIES TOTAL1 Multifocal contact lenses.
- Emphasis on tasks where it is advantageous to have objects simultaneously in focus over a large range of viewing distances.
- Expectations consistent with actual everyday visual demands.
- Motivated to wear lenses and understands that vision may not always be as sharp as with spectacles for some distances or lighting conditions.
- Unable to adapt to monovision correction.

**Less than Ideal Candidates**

- Critical or very fine visual demands at both distance and near.
- Refractive cylinder ≥ 1.00D (any axis) in one or both eyes or against-the-rule refractive cylinder > 1.00D in one or both eyes.
- Monocular distance acuities poorer than 20/20 with spherical equivalent refractive correction.
- Myopic anisometropia where the refractive error for one of the two eyes is low (≤1.50D) and has not been habitually corrected.
- Pupil size larger (> 4 mm) or smaller (<3 mm) than norm for presbyopic population under natural illumination conditions.
- Abnormal binocular sensory function (e.g., amblyopia or strabismus).
- Expectation to discard and never use spectacles again, including reading glasses, for special tasks or viewing conditions.
- Highly satisfied monovision wearers.
- Any other contraindications to successful contact lens wear such as tear abnormality or lid margin disease.
3. **Initial Lens Selection**

A. **Initial Base Curve Selection**

DAILIES TOTAL1* Multifocal (deleflon A) contact lenses are available in a single 8.5 mm base curve.

B. **Initial Lens Power Selection**

Note: A careful maximum plus spherocylindrical refraction and nearpoint add determination should be conducted prior to selecting a DAILIES TOTAL1* Multifocal (deleflon A) trial lens. Autorefraction findings should be refined manually to rule out effects of Instrument myopia and ensure proper control of residual accommodation.

The DAILIES TOTAL1* Multifocal lens design makes selecting the initial lens power easy. You need only manipulate the distance power. The optimum starting point is with a power that is equal to or more plus or less minus than the vertex corrected spherical equivalent spectacle refraction.

C. **Initial ADD Selection**

Note: A careful nearpoint ADD determination should be conducted prior to selecting a DAILIES TOTAL1* Multifocal (deleflon A) trial lens.

The DAILIES TOTAL1* Multifocal (deleflon A) 3 ADD SYSTEM allows personalized fitting for presbyopic patients. The table below makes initial ADD selection easy.

**DAILIES TOTAL1* MULTIFOCAL ADD SELECTION**

<table>
<thead>
<tr>
<th>SPECTACLE ADD</th>
<th>BOTH EYES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to +1.25</td>
<td></td>
</tr>
<tr>
<td>+1.50 to +2.00</td>
<td></td>
</tr>
<tr>
<td>+2.25 to +2.50</td>
<td></td>
</tr>
</tbody>
</table>

**Example 1:**

<table>
<thead>
<tr>
<th>OD</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spherical Rx: -4.50 -0.75 x 90</td>
<td>-4.00D</td>
</tr>
<tr>
<td>Spherical equivalent (least minus):</td>
<td>-4.75D</td>
</tr>
<tr>
<td>Vertex corrected power:</td>
<td>-4.50D</td>
</tr>
<tr>
<td>Spectacle Add:</td>
<td>+0.75D</td>
</tr>
<tr>
<td>Eye Dominance:</td>
<td>OD</td>
</tr>
<tr>
<td>Initial Trial Lens:</td>
<td>-4.50 LO</td>
</tr>
<tr>
<td></td>
<td>-4.00 LO</td>
</tr>
</tbody>
</table>
Example 2:

<table>
<thead>
<tr>
<th></th>
<th>OD</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spherical Rx:</td>
<td>+4.25 -0.25 x 180</td>
<td>+4.00 D</td>
</tr>
<tr>
<td></td>
<td>-0.50 x 180</td>
<td></td>
</tr>
<tr>
<td>Spherical equivalent (least minus):</td>
<td>+4.25D</td>
<td>+3.75D</td>
</tr>
<tr>
<td>Vertex corrected power:</td>
<td>+4.50D</td>
<td>+3.75D</td>
</tr>
<tr>
<td>Spectacle Add:</td>
<td></td>
<td>+2.00D</td>
</tr>
<tr>
<td>Eye Dominance:</td>
<td></td>
<td>OS</td>
</tr>
<tr>
<td>Initial Trial Lens:</td>
<td>+4.50 MED</td>
<td>+3.75 MED</td>
</tr>
</tbody>
</table>

4. Initial Lens Fitting Evaluation
a) Insert the lenses selected in Section 3 (above). If the exact power is not available, choose the next closest least minus/most plus lens power in your trial set.
b) Allow the lenses to settle on the eyes for approximately 10 minutes. This allows time for the patient to adapt to the lenses and time for the lens to equilibrate with the patient's tears.
c) Evaluate the fit of the lenses on the eye. The Push-up Test as described below is an important part of the lens evaluation. The following guidelines will be helpful in evaluating the physical fit of the lens:

Characteristics of a Well-fitted Lens
A well-fitted DAILIES TOTAL1 Multifocal (delefilcon A) contact lens satisfies the following criteria:

1. Full corneal coverage and good centration (no limbal exposure). A lens that is decentered > 1 mm, particularly temporal, is less likely to give adequate vision.

2. Lens movement of 0.1 to 0.5 mm should be present to allow tear exchange under the lens during a blink in primary gaze or upward gaze and to avoid variable vision.

Push-up Test:
- This test is a reliable indicator of a good fit. With the patient looking straight ahead, place your index finger on the patient's lower lid and nudge the edge of the lens upward while observing lens movement. Then pull the lid back down and observe the return of the lens.
- A well fitted lens will move freely upward, stopping shortly after passing the limbus and then return freely to its original position.

3. Good comfort.
4. Acceptable visual acuity with over-refraction.
Characteristics of a Tight (Steep) Lens Fit

A tight or steep fit should not be dispensed. If a lens fit is judged to be too steep a flatter lens (larger base curve), if available, should be evaluated. A tight or steep lens fit would display some or all of the following characteristics:

1. Good centration.
2. Insufficient or no lens movement during a blink in primary gaze or upward gaze.
3. Excessive conjunctival drag (visible movement of the conjunctival vessels when the lens moves during a blink or during the push-up test). Note: presbyopes often have loose conjunctiva, some conjunctival movement is occasionally seen and may not be a sign of a tight fit. See Push-up Test below.

Push-up Test:
- A tight fitting lens will resist movement. If successfully nudged upward, the lens may remain decentered or return slowly to its original position.
4. Good comfort.
5. Blurred vision between blinks.

Characteristics of a Loose (Flat) Lens Fit

If a lens fit is judged to be too flat a steeper lens (smaller base curve), if available, should be evaluated. A loose lens fit would display some or all of the following characteristics:

1. Decentration.
2. Excessive lens movement during the blink in primary or upward gaze.

Push-up Test:
- A loose fitting lens will move very easily, well beyond the limbus and possibly encroaching upon or going beyond the pupil. It will then return very quickly to its original position and often times return lower than its original position.
3. Reduced comfort.
4. Lens edge standoff.
5. Blurred vision immediately after the blink.

5. Initial Lens Visual Evaluation

While lenses are settling, it is helpful to take the patient from the exam room to a "real-world" setting such as a room with an outside view. Once an acceptable fit has been achieved, the visual performance of the lenses may be evaluated. Visual acuity is tested at distance. If necessary, a spherical over-refraction should be performed using a trial frame or hand held lenses rather than a phoropter. This technique is essential when fitting multifocal lenses because it allows the patient to maintain the head posture and direction of gaze (relationship between eye and head) that he or she would naturally use during everyday tasks. This ensures that the visual performance of the lens is being assessed under conditions where the on-eye positioning matches that which will occur when the lens is being used, for example, for near work activities. In addition, pupil size will not be artificially increased.
by the reduction in light associated with looking through the aperture of the phoropter cells, or decreased by proximal cues associated with the nearness of the instrument.

6. Fitting Procedures

Step 1. After the trial lenses have settled for approximately 10 minutes, measure distance acuity while the patient is viewing the chart binocularly (i.e., simultaneously with both eyes). Next, evaluate the patient's subjective impression of the near vision when trying to read typical everyday material (e.g., a newspaper, magazine, and cell phone). Lighting and reading distance should be what is normal for the patient.

Step 2. If distance or near vision is unsatisfactory, perform a binocular distance over-refraction, as follows. Use hand-held trial lenses and encourage plus. For example, if a Plano and +0.25D over-refraction yields the same results, use the +0.25D endpoint. Re-check visual acuity and visual quality as described in Step 1 above. If over-refraction is other than plano, go immediately to new trial lenses, keeping ADD the same.

Step 3. If distance and near vision are satisfactory, dispense lenses and remind patient to use good light when reading fine print or use additional reading glasses if needed. It is helpful to let the patient experience the lenses in their natural environment before further procedures for enhancing vision are performed.

Step 4. Enhanced Near Vision. If near vision is unsatisfactory, determine the dominant eye by the following method. Determine the eye with greatest plus acceptance by placing +1.50 handheld trial lens over each eye alternately while patient views in the distance with both eyes open. Consider the eye for which binocular vision blurs least with the +1.50 to be the non-dominant eye. Other methods to determine the dominant eye are appropriate.

Step 4A: Check the patient's binocular acuity with +0.50 over the non-dominant eye to determine if near vision is improved and distance vision is still acceptable. If so, place a new trial lens with the same ADD on the non-dominant eye, adjusting the distance power by +0.50.

<table>
<thead>
<tr>
<th>Enhanced near vision, Step A</th>
<th>SPECTACLE ADD</th>
<th>DOMINANT EYE</th>
<th>NON-DOMINANT EYE (PLUS ACCEPTED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to +1.25</td>
<td></td>
<td></td>
<td>with additional +0.50</td>
</tr>
<tr>
<td>+1.50 to +2.00</td>
<td></td>
<td></td>
<td>with additional +0.50</td>
</tr>
<tr>
<td>+2.25 to +2.50</td>
<td></td>
<td></td>
<td>with additional +0.50</td>
</tr>
</tbody>
</table>

Next, re-check visual acuity and visual quality as described in Step 1 above. If satisfactory, dispense new distance lens power for the non-dominant eye. If near vision is still unsatisfactory, proceed to Step B:
Step 4B: If near vision is still unsatisfactory, adjust ADD as shown below.

<table>
<thead>
<tr>
<th>SPECTACLE ADD</th>
<th>DOMINANT EYE</th>
<th>NON-DOMINANT EYE (PLUS ACCEPTED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to +1.25</td>
<td>🔄</td>
<td>🔄</td>
</tr>
<tr>
<td>+1.50 to +2.00</td>
<td>🔄</td>
<td>🔄</td>
</tr>
<tr>
<td>+2.25 to +2.50</td>
<td>🔄</td>
<td>🔄</td>
</tr>
</tbody>
</table>

Note: It is common to question the rather non-intuitive step we suggest for enhancing vision at near in the HI ADD range, where the suggestion is to “back off” to a MED ADD for the non-dominant eye, the same suggestion we make for enhancing distance vision (below). The reason for this is that after establishing (in Step A) that increasing plus is not helpful, the next most common reason for blur at near (or distance) is unacceptable ghosting that degrades the image quality. Backing down to the MED ADD in one eye can often relieve that and actually improve vision at near.

Step 5: Enhanced Distance Vision. If distance over-refraction did not improve visual acuity, adjust ADD according to the chart below.

<table>
<thead>
<tr>
<th>SPECTACLE ADD</th>
<th>DOMINANT EYE</th>
<th>NON-DOMINANT EYE (PLUS ACCEPTED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>+1.50 to +2.00</td>
<td>🔄</td>
<td>🔄</td>
</tr>
<tr>
<td>+2.25 to +2.50</td>
<td>🔄</td>
<td>🔄</td>
</tr>
</tbody>
</table>
Fitting Guidelines (Monovision)

Patient Selection

A. Monovision Needs Assessment

For a good prognosis, the patient should have adequately corrected distance and near visual acuity in each eye. Patients with reduced visual acuity, such as the amblyopic patient, may not be a good candidate for monovision.

Occupational and environmental visual demands should be considered. If the patient requires critical vision (visual acuity and stereopsis), it must be determined by trial whether this patient can function adequately with monovision. Monovision contact lens wear may not be optimal for such activities as:

1. visually demanding situations such as operating potentially dangerous machinery or performing other potentially hazardous activities; and
2. driving automobiles (e.g., driving at night). Patients who cannot pass requirements for a driver's license with monovision correction should not drive with this correction. An additional over-correction can be prescribed to improve vision.

B. Patient Education

All patients do not function equally well with monovision correction. Patients may not perform as well for certain tasks with this correction as they have with bifocal reading glasses. Each patient must understand that monovision, as well as other presbyopic contact lenses, or other alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. During the fitting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision in straight-ahead and upward gaze that monovision contact lenses provide compared to spectacle bifocals.

Eye Selection

Generally, the non-dominant eye is corrected for near vision. The following test for eye dominance can be used:

A). Ocular Preference Determination Methods

- Method 1 - Determine which eye is the "sight eye". Have the patient point to an object at the far end of the room. Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
- Method 2 - Determine which eye will accept the added power for near with the least reduction in distance vision. Place a trial spectacle near ADD lens in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.

B). Refractive Error Method

- For anisometropic corrections, it is generally best to fit the more hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
C). Visual Demands Method

- Consider the patient's occupation during the eye selection process to determine the critical vision requirements. If a patient's gaze for near tasks is usually in one direction, correct the eye on that side for near.

Example:
A person who places copy to the left side of the desk will usually function best with the near lens on the left eye.

Special Fitting Considerations

Unilateral Lens Correction

There are circumstances where only one contact lens is required. As an example, an emmetropic patient would only require a near lens while a bilateral myope may require only a distance lens.

- Examples:
- Emmetropic: A presbyopic emmetropic patient who requires a +1.75 diopter ADD would have a +1.75 lens on the near eye and the other eye left without a lens.
- Bilateral myope: A presbyopic patient requiring a +1.50 diopter ADD who is -2.50 diopters myopic in the right eye and -1.50 diopters myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
- Unilateral astigmat:
  a) Emmetropic in one eye, astigmatic in the other

<table>
<thead>
<tr>
<th>Spectacle Rx</th>
<th>Potential Monovision Rx</th>
</tr>
</thead>
<tbody>
<tr>
<td>O.D. Plano</td>
<td>Uncorrected for distance</td>
</tr>
<tr>
<td>O.S. -1.00 -1.00 x 090</td>
<td>+0.50 -1.00 x 090 for near</td>
</tr>
<tr>
<td>Add: +1.50</td>
<td></td>
</tr>
</tbody>
</table>

b) Myopic in one eye, astigmatic in the other

<table>
<thead>
<tr>
<th>Spectacle Rx</th>
<th>Potential Monovision Rx</th>
</tr>
</thead>
<tbody>
<tr>
<td>O.D. -1.50</td>
<td>Uncorrected for near</td>
</tr>
<tr>
<td>O.S. -2.00 -1.75 x 090</td>
<td>-2.00 -1.75 x 090 for distance</td>
</tr>
</tbody>
</table>

Amblyopia

The amblyopic patient may not be a good candidate for monovision.

Astigmatism

Patients with less than 1.50 diopters of astigmatism might be successfully fit in DAILIES TOTAL1+ (delefi con A) spherical lenses.

- Determine which eye to use for the near prescription (see Eye Selection, A-C, above)
- Add the appropriate near add power to the spherical component of the astigmatic prescription for that eye.
Example: Spectacle Rx
O.D.: -2.50 -0.75 x 180
O.S.: -3.00 -1.75 x 165
Add: +1.00
Dominant eye: O.D.

Potential Monovision Rx
-2.50 -0.75 x 180 for distance
-2.00 -1.75 x 165 for near

Near Add Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient's habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.

Trial Lens Fitting
A trial lens fitting is performed in the office to allow the patient to experience monovision correction. Lenses are fit according to the directions in the General Fitting Guidelines and Base Curve Selection described earlier in the guide. Case history and standard clinical evaluation procedures should be used to determine the suitability of monovision. Determine which eye is to be corrected for distance and which eye is to be corrected for near. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction. Immediately after the correct power lenses are in place, walk across the room and have the patient look at you. Assess the patient's reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or fingernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tasks are completed, should the patient be asked to read print. Evaluate the patient's reaction to large print (e.g., typewritten copy) at first and then graduate to news print and finally smaller type sizes. After evaluating the patient's performance under the above conditions, tests of visual acuity and reading ability under conditions of moderately dim illumination should be attempted. An initial unfavorable response in the office, while indicative of a less favorable prognosis, should not immediately rule out a more extensive trial under the usual conditions in which a patient functions.

Adaptation
Visually demanding situations should be avoided during the initial wearing period. A patient may at first experience some mild blurred vision, dizziness, headaches, and feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a few minutes or for several weeks. The longer these symptoms persist, the poorer the chance for successful adaptation. To help in the adaptation process, the patient can be advised to first use the lenses in a comfortable, familiar environment such as in the home. Some patients feel that automobile driving performance may not be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it is recommended that patients be a passenger first to make sure that their vision is satisfactory for operating an automobile. During the first several
weeks of wear (when adaptation is occurring), it may be advisable for the patient
to only drive under optimal driving conditions. After adaptation, and success with
these activities, the patient should be able to drive under other conditions with
cautions.

Other Suggestions
The success of the monovision technique may be further improved by having your
patient follow the suggestions below:

- Have a third contact lens (distance power) to use when critical distance
  viewing is needed.
- Have a third contact lens (near power) to use when critical near viewing
  is needed.
- Have supplemental spectacles to wear over the monovision contact
  lenses for specific visual tasks. This is particularly applicable for
  those patients who cannot meet driver's licensing requirements with a
  monovision correction.
- Make use of proper illumination when carrying out visual tasks.

Success in fitting monovision can be improved by the following suggestions:

- Reverse the distance and near eyes if a patient is having trouble adapting.
- Refine the lens powers if there is trouble with adaptation. Accurate lens
  power is critical for presbyopic patients.
- Emphasize the benefits of the clear near vision in straight ahead and
  upward gaze with monovision.

The decision to fit a patient with a monovision correction is most appropriately
left to the eye care professional in conjunction with the patient after carefully
considering the patient's needs. All patients should be supplied with a copy
of the Patient Instruction Booklet, which contains important instructions
for the monovision wearer. You can obtain copies of the instruction book by
calling customer service in the USA at (800) 241-5999.

DISPENSING VISIT
To help ensure patient success the following steps should be conducted with
each patient, even if they have previously worn contact lenses. Even experienced
wearers are prone to develop bad habits over time.

DAILIES TOTAL1* brand (deleficon A) lenses are supplied sterile in foil sealed
blister pack containers. Open the foil pack by peeling back the foil lidding material
and gently slide the lens out of the container with your finger, or pour the lens onto
the palm of your clean hand.

Conduct the following steps with each patient, even if they have previously worn
contact lenses:

A. Verification of Lens Fit
Evaluate lens fit and visual response with the lens on the eye. The criteria
of a well-fitted lens should be met and the patient's visual acuity should be
acceptable. If not, the patient should be refitted with a more appropriate
lens.

B. Hygiene and Lens Handling Instructions
Good hygiene and proper lens handling are important factors in achieving
safe, comfortable lens wear. Instruct the patient on hygiene and handling
of lenses. Patients who are unable to place and remove lenses should not
be provided with them.
C. Lens Wear and Replacement Schedules (see Package Insert)
Prescribe and explain the daily disposable wear schedule. Explain that lenses are to be discarded after each daily wearing period. Determine the maximum suggested daily wearing period based on the patient's physiological eye condition. There may be a tendency for the patient to overwear their lenses initially. For some patients who have never worn contact lenses consider a wearing schedule that allows for a gradual increase in wearing time.

D. Lens Care Directions (see Package Insert)
The lenses are not intended to be cleaned or disinfected and should be discarded after a single use. The eye care professional may recommend lens rewetting drops, as needed.

E. Specific Instructions for Presbyopic Patients
Specific instructions, explanations and demonstrations are important for optimizing patient success with multifocal contact lenses. The following information and instructions have proven useful in advising patients who wear DAILIES TOTAL1 Multifocal (delefolicon A) soft contact lenses.

- A contact lens that contains different powers for distance and near involves greater technological and optical complexity than does a bifocal or multifocal spectacle lens. This is because the contact lens moves with the eye, rather than having the eye move up and down while the lens remains suspended in a frame. While the contact lens therefore gives an unobstructed field of view and greater freedom regarding where to look, these advantages may mean that the sharpness of vision may not always be exactly the same as what would be experienced with spectacles.

- Although many individuals use DAILIES TOTAL1 Multifocal (delefolicon A) contact lenses for full-time wear, it is not unusual to find that there may be some activities where one prefers to wear spectacles, or where the disadvantages associated with spectacles are outweighed by other issues. This is an entirely normal and natural response to the challenges presented by presbyopia.

- Situations where vision with multifocal contact lenses may be less sharp or otherwise "different" than what is experienced with spectacles often involve low illumination (e.g., a semi-dark room), reduced visibility (e.g., outdoor conditions of fog or heavy rain), or isolated sources of very bright light (e.g., headlights of an oncoming vehicle on a narrow country road). Patients should be instructed to make use of good light when reading fine print.

- Patients should be aware that it might be advisable to refrain from wearing their lenses while driving, flying an airplane or operating heavy machinery while wearing their lenses until they gain some experience with the lenses in a similar visual environment.

- Small changes in lens power can often make a significant difference in the quality of the vision experienced with multifocal contact lenses. Such changes can be best tailored to
individual needs and environmental conditions that the patient will personally encounter on a day-to-day basis. Confidence and assurance that such refinements, if needed, can be achieved are important for patient motivation during the initial period of lens wear.

F. Additional Instructions
   • Review the Package Insert
     Provide the patient with all relevant information and precautions on the proper use of the lenses that are prescribed.
   • Provide the Patient Instruction Booklet for DAILIES TOTAL1* and DAILIES TOTAL4 Multifocal (delefilm A) Contact Lenses.
     Give the patient a copy of the Patient Instruction Booklet for DAILIES TOTAL1* and DAILIES TOTAL4 Multifocal (delefilm A) soft contact lenses. Review the contents so the patient clearly understands the prescribed lens wear, care, and replacement schedule. In the USA you can obtain copies of the instruction book by calling Alcon customer service at (800) 241-5999.

Follow-Up Examinations
Follow-up care is extremely important for continued successful contact lens wear. Follow-up care should include:
   • Case history, including questions to identify any problems related to contact lens wear
   • Management of specific problems, if any, and
   • A review with the patient of the lens wearing schedule, replacement schedule and handling procedures.

Follow-up Examination Procedures
   • Patients should be instructed to wear lenses prior to a follow-up examination.
   • Record patient’s symptoms, if any.
   • Measure visual acuity monocularly and binocularly with the contact lenses in place.
   • Perform an over-refraction to check for residual refractive error.
   • With a biomicroscope, evaluate lens fitting.
   • Remove the lenses and conduct a thorough biomicroscopic examination with fluorescein. Rinse eyes with saline before re-inserting lenses.
   • Evert upper lids to determine condition of tarsal conjunctiva.
   • Periodically perform keratometry and spectacle refractions. These results should be recorded to compare to the initial measurements.
   • If any observations are abnormal, use professional judgment to manage the problem and restore the eye to optimal conditions. If visual requirements are not satisfied during any follow-up examination, the patient should be re-fitted with a more appropriate lens.

LENS HANDLING HINTS
Lens Insertion
   • When about to place the lens on the eye, make sure the lens sits up on the placement finger. The finger should be dry so surface tension does
not cause the lens to adhere to the finger.

- Check to see that the lens is right side out. A lens that is placed on the eye inside out may not feel comfortable or provide good vision.

One way to do this is to perform the 'taco test' by placing the lens between your thumb and index finger and squeeze the edges together gently.

- If the edges come together, the lens is right side out.
- If the edges turn outward, the lens is wrong side out. Carefully reverse it with your fingers.

![Correct Incorrect](image)

Another way is to place the lens on the tip of your index finger and check its shape.

- If the edge appears bowl-shaped, it is right side out.
- If the edge has a lip or flares outward, it is wrong side out and must be reversed.
- Place the lens directly onto the cornea (placing it on the lower sclera can lead to the lens folding after a blink). While continuing to hold both lids in place, the patient should look down to seat the lens. The lids may then be released.

![Correct Incorrect](image)

**Lens Removal**

- Wash hands thoroughly with soap that does not have any oils, lotions or perfumes.
- Carefully dry hands with a clean, lint-free towel.

It is important to remind patients to dry their hands thoroughly prior to removing their lenses. The surface of DAILIES TOTAL1® brand lenses is designed to stay very wet and lubricious, or slippery while on the eye. If their fingertips are wet they are likely to slip across the surface of the lens making removal more difficult.

- Slide the lens off the cornea (down or to the side) onto the sclera. This produces a fold in the lens, which assists in removal. With the index finger and thumb, gently pinch the lens off the eye.
- Discard lenses.
Care for a Sticking Lens

- In the unlikely event that the lens sticks (stops moving) or begins to dry on the eye, instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens begins to move freely on the eye before attempting to remove it. If the lens continues to stick, the patient should immediately consult the eye care professional.

IN OFFICE CARE OF TRIAL LENSES

Eye care professionals should understand and educate contact lens technicians concerning proper use of trial lenses.

- Each contact lens is shipped sterile in a sealed blister pack containing phosphate buffered saline with additives. Hands should be thoroughly washed and rinsed and dried with a lint-free towel prior to handling a lens. In order to insure sterility, the blister pack should not be opened until immediately prior to use.
- Delefsion A lenses are for daily disposable wear only and should be discarded after a single use. The lenses should be disposed of after a single use and not be re-used from patient to patient.

ADDITIONAL INFORMATION

For assistance with fitting or clinical questions regarding DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal contact lenses eye care professionals having questions or problems should contact Medical Information Systems in the USA at (800) 241-7488. To order DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal contact lenses contact your Alcon sales representative or call Customer Service, in the USA at (800) 241-5999.
## VERTEX DISTANCE CONVERSION CHART
For minus lenses, read left to right; for plus lenses, read right to left.
(12 mm Vertex Distance)

<p>| | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4.00</td>
<td>3.87</td>
<td>7.50</td>
<td>6.87</td>
<td>12.00</td>
<td>10.37</td>
<td>19.00</td>
<td>15.50</td>
</tr>
<tr>
<td>4.25</td>
<td>4.00</td>
<td>7.62</td>
<td>7.00</td>
<td>12.50</td>
<td>10.75</td>
<td>19.25</td>
<td>15.62</td>
</tr>
<tr>
<td>4.50</td>
<td>4.25</td>
<td>7.75</td>
<td>7.12</td>
<td>12.75</td>
<td>11.00</td>
<td>19.25</td>
<td>15.75</td>
</tr>
<tr>
<td>4.75</td>
<td>4.50</td>
<td>7.87</td>
<td>7.25</td>
<td>13.00</td>
<td>11.25</td>
<td>19.75</td>
<td>16.00</td>
</tr>
<tr>
<td>5.00</td>
<td>4.75</td>
<td>8.00</td>
<td>7.37</td>
<td>13.50</td>
<td>11.50</td>
<td>20.00</td>
<td>16.12</td>
</tr>
<tr>
<td>5.12</td>
<td>4.87</td>
<td>8.12</td>
<td>7.50</td>
<td>13.75</td>
<td>11.75</td>
<td>20.25</td>
<td>16.25</td>
</tr>
<tr>
<td>5.37</td>
<td>5.00</td>
<td>8.25</td>
<td>7.62</td>
<td>14.00</td>
<td>12.00</td>
<td>20.50</td>
<td>16.50</td>
</tr>
<tr>
<td>5.50</td>
<td>5.12</td>
<td>8.50</td>
<td>7.75</td>
<td>14.25</td>
<td>12.25</td>
<td>20.75</td>
<td>16.62</td>
</tr>
<tr>
<td>5.62</td>
<td>5.25</td>
<td>8.75</td>
<td>8.00</td>
<td>14.75</td>
<td>12.50</td>
<td>21.00</td>
<td>16.76</td>
</tr>
<tr>
<td>5.75</td>
<td>5.37</td>
<td>9.00</td>
<td>8.25</td>
<td>15.00</td>
<td>12.75</td>
<td>21.25</td>
<td>17.00</td>
</tr>
<tr>
<td>5.87</td>
<td>5.50</td>
<td>9.25</td>
<td>8.37</td>
<td>15.50</td>
<td>12.75</td>
<td>21.75</td>
<td>17.25</td>
</tr>
<tr>
<td>6.00</td>
<td>5.62</td>
<td>9.50</td>
<td>8.62</td>
<td>15.75</td>
<td>13.25</td>
<td>22.25</td>
<td>17.60</td>
</tr>
<tr>
<td>6.12</td>
<td>5.75</td>
<td>9.75</td>
<td>8.75</td>
<td>16.25</td>
<td>13.50</td>
<td>22.50</td>
<td>17.75</td>
</tr>
<tr>
<td>6.37</td>
<td>5.87</td>
<td>10.00</td>
<td>9.00</td>
<td>16.75</td>
<td>13.75</td>
<td>23.00</td>
<td>18.00</td>
</tr>
<tr>
<td>6.50</td>
<td>6.00</td>
<td>10.25</td>
<td>9.12</td>
<td>17.00</td>
<td>14.00</td>
<td>23.50</td>
<td>18.25</td>
</tr>
<tr>
<td>6.87</td>
<td>6.37</td>
<td>11.00</td>
<td>9.62</td>
<td>18.00</td>
<td>14.50</td>
<td>24.75</td>
<td>19.00</td>
</tr>
<tr>
<td>7.00</td>
<td>6.50</td>
<td>11.25</td>
<td>9.75</td>
<td>18.12</td>
<td>14.75</td>
<td>25.00</td>
<td>19.25</td>
</tr>
<tr>
<td>7.12</td>
<td>6.62</td>
<td>11.50</td>
<td>10.00</td>
<td>18.50</td>
<td>15.00</td>
<td>25.50</td>
<td>19.50</td>
</tr>
<tr>
<td>7.37</td>
<td>6.75</td>
<td>11.75</td>
<td>10.25</td>
<td>18.75</td>
<td>15.25</td>
<td>26.00</td>
<td>19.75</td>
</tr>
</tbody>
</table>
DAILIES TÂTES® and DAILIES TÂTES TÂTES Multifocal (deleion A) Soft Contact Lenses for Daily Disposable Wear

Precautions

PREScribing CONSIDERATIONS

GROSS DAILIES TÂTES (multifocal) are intended for use in both near and far vision. However, the lens can be worn continuously. The use of multifocal lenses may result in increased awareness of any underlying contributory disease states. Therefore, patients should be referred to an eye specialist for evaluation and management.

DAILIES TÂTES TÂTES Multifocal (deleion A) are intended for use in both near and far vision. The use of multifocal lenses may result in increased awareness of any underlying contributory disease states. Therefore, patients should be referred to an eye specialist for evaluation and management.

Contact lenses are not prescriptive. They cannot be worn continuously. The use of multifocal lenses may result in increased awareness of any underlying contributory disease states. Therefore, patients should be referred to an eye specialist for evaluation and management.

Advise patients who are using multifocal lenses to consult their eye specialist for evaluation and management.

When prescribing contact lenses, the prescriber should consider the patient's ocular health, visual requirements, and lifestyle. The DAILIES TÂTES and DAILIES TÂTES TÂTES Multifocal (deleion A) lenses are intended for daily use.

Contact lenses are not prescriptive. They cannot be worn continuously. The use of multifocal lenses may result in increased awareness of any underlying contributory disease states. Therefore, patients should be referred to an eye specialist for evaluation and management.

Advising patients who are using multifocal lenses to consult their eye specialist for evaluation and management.

Contact lenses are not prescriptive. They cannot be worn continuously. The use of multifocal lenses may result in increased awareness of any underlying contributory disease states. Therefore, patients should be referred to an eye specialist for evaluation and management.

Advising patients who are using multifocal lenses to consult their eye specialist for evaluation and management.
• The care professional must be consulted about any serious medical condition or injury.
• History of any medication, previous surgery, or allergic reaction.
• Diagnosis and treatment plan should be provided to the patient.
• The patient must be informed of the potential for complications, risks, and alternatives.
• The patient must be informed of the importance of following post-operative instructions.
• The patient must be informed of the importance of maintaining a healthy lifestyle.

ADVERSE EFFECTS AND PREVENTION
• Adverse effects may include pain, swelling, bruising, numbness, and weakness.
• Adverse effects may include infection, delayed healing, and scar formation.
• Adverse effects may include nerve damage, muscle weakness, and joint stiffness.
• Adverse effects may include loss of function, loss of sensation, and loss of mobility.

PRECAUTIONS
• Precautions should be taken before any procedure.
• Precautions should be taken during any procedure.
• Precautions should be taken after any procedure.
• Precautions should be taken throughout the recovery period.

CONTRAINDICATIONS
• Contraindications should be considered before any procedure.
• Contraindications should be considered during any procedure.
• Contraindications should be considered after any procedure.
• Contraindications should be considered throughout the recovery period.

MINT CONDITIONS
• Mint conditions should be considered before any procedure.
• Mint conditions should be considered during any procedure.
• Mint conditions should be considered after any procedure.
• Mint conditions should be considered throughout the recovery period.

WARNING
• The patient must be informed of the potential for complications, risks, and alternatives.
• The patient must be informed of the importance of following post-operative instructions.
• The patient must be informed of the importance of maintaining a healthy lifestyle.

INFORMATION
• Information should be provided to the patient before any procedure.
• Information should be provided during any procedure.
• Information should be provided after any procedure.
• Information should be provided throughout the recovery period.

PATIENT INFORMATION
• Patient information should be provided before any procedure.
• Patient information should be provided during any procedure.
• Patient information should be provided after any procedure.
• Patient information should be provided throughout the recovery period.

THE PATIENT'S RIGHT TO REFUSE
• The patient has the right to refuse any treatment or procedure.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.

THE PATIENT'S RIGHT TO FREE CHOICE
• The patient has the right to make an informed decision.
• The patient may request additional information or clarification.
• The patient may request to speak to a different professional.
• The patient may request to see a different professional.

THE PATIENT'S RESPONSIBILITY
• The patient is responsible for following the treatment plan.
• The patient is responsible for reporting any changes in their health.
• The patient is responsible for reviewing any medical records.
• The patient is responsible for ensuring that all medical information is accurate.
This page intentionally left blank
APPENDIX 1: CLINICAL TECHNICAL PROCEDURES

- LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS
- EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING
- DETERMINATION OF NEAR ADD
- NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE
- LENS FITTING CHARACTERISTICS
- SUBJECT REPORTED OCULAR SYMPTOMS
- DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
- BIOMICROSCOPY SCALE
- KERATOMETRY PROCEDURE
- DISTANCE AND NEAR VISUAL ACUITY EVALUATION
- ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE
- MEASURING PUPIL DIAMETER WITH NEUROPTICS VIP-200 VARIABLE PUPILLOMETER
LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS
Limbal & Conjunctival (Bulbar) Redness
EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING
DETERMINATION OF NEAR ADD
SUBJECT REPORTED OCULAR SYMPTOMS
### Subject Reported Ocular Symptoms/Problems

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### REQUIREMENTS
DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
Determination of Distance Spherocylindrical Refractions

<table>
<thead>
<tr>
<th>Table of Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distance (m)</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>1.23</td>
</tr>
<tr>
<td>2.45</td>
</tr>
<tr>
<td>3.67</td>
</tr>
<tr>
<td>4.89</td>
</tr>
</tbody>
</table>

Diagram showing spherocylindrical refraction with distances and angles marked.
BIOMICROSCOPY SCALE
MEASURING PUPIL DIAMETER WITH NEUROPTICS VIP-200 VARIABLE PUPILLOMETER
Pupil Diameter with NeurOptics VIP-200 Variable Pupillometer
Protocol Number and Title: CR-5860 Evaluation of Two Marketed Multifocal Contact Lenses
Version and Date: v3.0 Amendment 2.0, 01-SEPT-2017

I have read and understand the protocol specified above and agree on its content.

I agree to conduct this study according to GCP and ICH guidelines, the Declaration of Helsinki, ISO 14155, United States (US) Code of Federal Regulations (CFR), and the pertinent individual country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The Principal Investigator is responsible for ensuring that all clinical site personnel, including Sub-Investigators adhere to all ICH regulations and GCP guidelines regarding clinical trials during and after study completion.

I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.

I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all ICH regulations and GCP guidelines regarding clinical trials during and after study completion.

All clinical site personnel involved in the conduct of this study have completed Human Subjects Protection Training.

I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their obligations in meeting the above commitments.

I shall not disclose the information contained in this protocol or any results obtained from this study without written authorization.

Principal Investigator:

Signature __________________________ Date __________________________

Name and Professional Position (Printed)

Institution/Site:

Institution/Site Name

Institution/Site Address